Zion Oil & Gas (ZNOG) 10-Q 10 Aug 23 2023 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 08, 2023
Document Information Line Items
Entity Registrant Name	ZION OIL & GAS, INC.
Trading Symbol	N/A
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		579,095,530
Amendment Flag	false
Entity Central Index Key	0001131312
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-0065053
Entity Address, Address Line One	12655 N Central Expressway
Entity Address, Address Line Two	Suite 1000
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75243
City Area Code	(214)
Local Phone Number	221-4610
Title of 12(b) Security	N/A
Security Exchange Name	NONE
Entity Interactive Data Current	Yes
Entity File Number	001-33228

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Cash and cash equivalents	$ 518	$ 1,735
Fixed short term bank and escrow deposits – restricted	1,040	1,379
Prepaid expenses and other current assets	394	600
Other deposits		483
Governmental receivables	16	267
Other receivables	158	143
Total current assets	2,126	4,607
Unproved oil and gas properties, full cost method (see Note 4)	16,191	15,889
Property and equipment at cost
Drilling rig and related equipment, net of accumulated depreciation of $1,835 and $1,455 (see note 2I)	5,890	6,281
Property and equipment, net of accumulated depreciation of $668 and $647	91	112
Property plant and equipment net	5,981	6,393
Right of Use Lease Assets (see Note 5)	79	202
Other assets
Assets held for severance benefits	438	424
Total other assets	438	424
Total assets	24,815	27,515
Current liabilities
Accounts payable	1,121	2,147
Lease obligation – current (see Note 5)	67	196
Asset retirement obligation	571	571
Accrued liabilities	729	1,032
Total current liabilities	2,488	3,946
Long-term liabilities
Lease obligation – non-current (see Note 5)	12	12
Provision for severance pay	465	457
Total long-term liabilities	477	469
Total liabilities	2,965	4,415
Commitments and contingencies (see Note 6)
Stockholders’ equity
Common stock, par value $.01; Authorized: 1,200,000,000 shares at June 30, 2023: Issued and outstanding: 560,449,580 and 524,231,493 shares at June 30, 2023 and December 31, 2022, respectively	5,604	5,242
Additional paid-in capital	299,321	296,460
Accumulated deficit	(283,075)	(278,602)
Total stockholders’ equity	21,850	23,100
Total liabilities and stockholders’ equity	$ 24,815	$ 27,515

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parentheticals) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Drilling rig and related equipment, net of accumulated depreciation (in Dollars)	$ 1,835	$ 1,455
Accumulated depreciation (in Dollars)	$ 668	$ 647
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, authorized	1,200,000,000	1,200,000,000
Common stock, issued	560,449,580	524,231,493
Common stock, outstanding	560,449,580	524,231,493

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
General and administrative	$ 1,271	$ 1,550	$ 2,774	$ 2,985
Post impairment of unproved oil and gas properties	48		93
Other	1,016	946	1,599	1,657
Loss from operations	(2,335)	(2,496)	(4,466)	(4,642)
Other income (expense), net
Foreign exchange loss	(2)	(81)	(4)	(90)
Financial income (expenses), net	3	(20)	(3)	(31)
Loss, before income taxes	(2,334)	(2,597)	(4,473)	(4,763)
Income taxes
Net loss	$ (2,334)	$ (2,597)	$ (4,473)	$ (4,763)
Net (loss), gain per share of common stock, Basic (in Dollars per share)	$ (4)	$ (10)	$ (8)	$ (10)
Weighted-average shares outstanding Basic (in Shares)	542,812	471,946	536,950	439,039

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Operations (Unaudited) (Parentheticals) - $ / shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Net (loss), gain per share of common stock, diluted	$ (4)	$ (10)	$ (8)	$ (10)
Weighted-average shares outstanding, diluted	542,812	471,946	536,950	439,039

Consolidated Condensed Statem_3

Consolidated Condensed Statement of Changes in Stockholders’ Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock		Additional paid-in Capital	Accumulated deficit	Total
Balances at Dec. 31, 2021	$ 3,643		$ 277,258	$ (223,525)	$ 57,376
Balances (in Shares) at Dec. 31, 2021	364,324
Funds received from sale of DSPP units and shares and exercise of warrants	$ 1,094		11,899		12,993
Funds received from sale of DSPP units and shares and exercise of warrants (in Shares)	109,349
Funds received from option exercises	$ 1				1
Funds received from option exercises (in Shares)	105
Value of options granted to employees, directors and others as non-cash compensation			635		635
Net loss				(4,763)	(4,763)
Balances at Jun. 30, 2022	$ 4,738		289,792	(228,288)	66,242
Balances (in Shares) at Jun. 30, 2022	473,778
Balances at Mar. 31, 2022	$ 4,666		287,878	(225,691)	66,853
Balances (in Shares) at Mar. 31, 2022	466,593
Funds received from sale of DSPP units and shares and exercise of warrants	$ 72		1,494		1,566
Funds received from sale of DSPP units and shares and exercise of warrants (in Shares)	7,130
Funds received from option exercises		[1]				[1]
Funds received from option exercises (in Shares)	55
Value of options granted to employees, directors and others as non-cash compensation			420		420
Net loss				(2,597)	(2,597)
Balances at Jun. 30, 2022	$ 4,738		289,792	(228,288)	66,242
Balances (in Shares) at Jun. 30, 2022	473,778
Balances at Dec. 31, 2022	$ 5,242		296,460	(278,602)	23,100
Balances (in Shares) at Dec. 31, 2022	524,231
Funds received from sale of DSPP units and shares and exercise of warrants	$ 360		2,366		2,726
Funds received from sale of DSPP units and shares and exercise of warrants (in Shares)	36,068
Funds received from option exercises	$ 2		10		12
Funds received from option exercises (in Shares)	150
Costs associated with the issuance of shares			(173)		(173)
Value of options granted to employees, directors and others as non-cash compensation			658		658
Net loss				(4,473)	(4,473)
Balances at Jun. 30, 2023	$ 5,604		299,321	(283,075)	21,850
Balances (in Shares) at Jun. 30, 2023	560,449
Balances at Mar. 31, 2023	$ 5,337		297,582	(280,741)	22,178
Balances (in Shares) at Mar. 31, 2023	533,713
Funds received from sale of DSPP units and shares and exercise of warrants	$ 266		1,668		1,934
Funds received from sale of DSPP units and shares and exercise of warrants (in Shares)	26,711
Funds received from option exercises	$ 1		3		4
Funds received from option exercises (in Shares)	25
Costs associated with the issuance of shares			(173)		(173)
Value of options granted to employees, directors and others as non-cash compensation			241		241
Net loss				(2,334)	(2,334)
Balances at Jun. 30, 2023	$ 5,604		$ 299,321	$ (283,075)	$ 21,850
Balances (in Shares) at Jun. 30, 2023	560,449
[1] Less than one thousand.

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net loss	$ (4,473)	$ (4,763)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	401	392
Cost of options issued to employees, directors and others as non-cash compensation	658	618
Post impairment of unproved oil and gas properties	93
Change in assets and liabilities, net:
Other deposits	483	68
Prepaid expenses and other	206	252
Governmental receivables	251	36
Lease obligation – current	(129)	58
Lease obligation – non current		(86)
Right of use lease assets	123	(8)
Other receivables	(15)	325
Severance payable, net	(6)	27
Accounts payable	(168)	(357)
Accrued liabilities	184	14
Net cash used in operating activities	(2,392)	(3,424)
Cash flows from investing activities
Acquisition of property and equipment		(15)
Acquisition of drilling rig and related equipment		(346)
Investment in unproved oil and gas properties	(1,729)	(8,087)
Net cash used in investing activities	(1,729)	(8,448)
Cash flows from financing activities
Proceeds from exercise of stock options	12	1
Costs paid related to the issuance of new shares	(173)
Proceeds from issuance of stock and exercise of warrants	2,726	12,993
Net cash provided by financing activities	2,565	12,994
Net (decrease)/increase in cash, cash equivalents and restricted cash	(1,556)	1,122
Cash, cash equivalents and restricted cash – beginning of period	3,114	5,952
Cash, cash equivalents and restricted cash – end of period	1,558	7,074
Non-cash investing and financing activities:
Unpaid investments in oil & gas properties	806	1,691
Cost of options issued to employees attributed to oil and gas properties		17
New lease accounted for as a right of use lease asset		$ 136

Consolidated Condensed Statem_5

Consolidated Condensed Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Income Statement [Abstract]
Cash and cash equivalents	$ 518	$ 1,735	$ 5,755	$ 4,683
Restricted cash included in fixed short-term bank deposits	1,040	1,379	1,319	1,269
Total	$ 1,558	$ 3,114	$ 7,074	$ 5,952

Nature of Operations, Basis of

Nature of Operations, Basis of Presentation and Going Concern	6 Months Ended
	Jun. 30, 2023
Nature of Operations, Basis of Presentation and Going Concern [Abstract]
Nature of Operations, Basis of Presentation and Going Concern	Note 1 - Nature of Operations, Basis of Presentation and Going Concern A. Nature of Operations Zion Oil & Gas, Inc., a Delaware corporation (“we,” “our,” “Zion” or the “Company”) is an oil and gas exploration company with a history of 23 years of oil & gas exploration in Israel. As of June 30, 2023, the Company has no revenues from its oil and gas operations. Zion maintains its corporate headquarters in Dallas, Texas. The Company also has branch offices in Caesarea, Israel and Geneva, Switzerland. The purpose of the Israel branch is to support the Company’s operations in Israel, and the purpose of the Switzerland branch is to operate a foreign treasury center for the Company. On January 24, 2020, Zion incorporated a wholly owned subsidiary, Zion Drilling, Inc., a Delaware corporation, for the purpose of owning a drilling rig, related equipment and spare parts, and on January 31, 2020, Zion incorporated another wholly owned subsidiary, Zion Drilling Services, Inc., a Delaware corporation, to act as the contractor providing such drilling services. When Zion is not using the rig for its own exploration activities, Zion Drilling Services may contract with other operators in Israel to provide drilling services at market rates then in effect. Zion has the trademark “ZION DRILLING” filed with the United States Patent and Trademark Office. Zion has the trademark filed with the World Intellectual Property Organization in Geneva, Switzerland, pursuant to the Madrid Agreement and Protocol. In addition, Zion has the trademark filed with the Israeli Trademark Office in Israel. Exploration Rights/Exploration Activities New Megiddo License 428 (“NML 428 ”) The New Megiddo License 428 (“NML 428”) was initially awarded on December 3, 2020 for a six-month term and was extended several times before expiring on February 1, 2023. Zion Oil & Gas, Inc. filed an amended application with the Israel Ministry of Energy for a new exploratory license on January 24, 2023 covering the same area as its License No. 428, which expired on February 1, 2023. However, its original application to replace License No. 428 was filed on May 11, 2022, and a revised application was filed on August 29, 2022. Prior to the filing of our last Quarterly Report, we received initial administrative approval from various departments within the Israel Ministry of Energy which puts us in an excellent position to obtain final approval of our license. We continue our exploration focus here based on our studies as it appears to possess the key geologic ingredients of an active petroleum system with significant exploration potential. We have finalized the technical and operational preparations for our re-entry of the MJ-01 well. B. Basis of Presentation The accompanying unaudited interim consolidated condensed financial statements of Zion Oil & Gas, Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring accruals necessary for a fair statement of financial position, results of operations and cash flows, have been included. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and the accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The year-end balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by GAAP. The results of operations for the three and six months ended June 30, 2023 are not necessarily indicative of the operating results for the year ending December 31, 2023 or for any other subsequent interim period. C. Going Concern The Company incurs cash outflows from operations, and all exploration activities and overhead expenses to date have been financed by way of equity or debt financing. The recoverability of the costs incurred to date is uncertain and dependent upon achieving significant commercial production of hydrocarbons. The Company’s ability to continue as a going concern is dependent upon obtaining the necessary financing to undertake further exploration and development activities and ultimately generating profitable operations from its oil and natural gas interests in the future. The Company’s current operations are dependent upon the adequacy of its current assets to meet its current expenditure requirements and the accuracy of management’s estimates of those requirements. Should those estimates be materially incorrect, the Company’s ability to continue as a going concern may be impaired. The consolidated financial statements have been prepared on a going concern basis, which contemplates realization of assets and liquidation of liabilities in the ordinary course of business. During the six months ended June 30, 2023, the Company incurred a net loss of approximately $4.5 million and had an accumulated deficit of approximately $283 million. These factors raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date the financials were issued. To carry out planned operations, the Company must raise additional funds through additional equity and/or debt issuances or through profitable operations. There can be no assurance that this capital or positive operational income will be available to the Company, and if it is not, the Company may be forced to curtail or cease exploration and development activities. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies A. Net Loss per Share Data Basic and diluted net loss per share of common stock, par value $0.01 per share (“Common Stock”) is presented in conformity with ASC 260-10 “Earnings Per Share.” Diluted net loss per share is the same as basic net loss per share as the inclusion of 56,933,841 and 56,876,638 and 37,061,435 and 34,216,856 Common Stock equivalents in the three and six-month period ended June 30, 2023 and 2022 respectively, would be anti-dilutive. B. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of expenses. Such estimates include the valuation of unproved oil and gas properties, deferred tax assets, asset retirement obligations, borrowing rate of interest consideration for leases accounting and legal contingencies. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity, foreign currency, and energy markets have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the consolidated financial statements in future periods. The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international markets. We have made estimates of the impact of COVID-19 within our consolidated financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods. Actual results may differ from these estimates. C. Oil and Gas Properties and Impairment The Company follows the full-cost method of accounting for oil and gas properties. Accordingly, all costs associated with acquisition, exploration and development of oil and gas reserves, including directly related overhead costs, are capitalized. All capitalized costs of oil and gas properties, including the estimated future costs to develop proved reserves, are amortized on the unit-of-production method using estimates of proved reserves. Investments in unproved properties and major development projects are not amortized until proved reserves associated with the projects can be determined or until impairment occurs. If the results of an assessment indicate that the properties are impaired, the amount of the impairment is included in loss from continuing operations before income taxes, and the adjusted carrying amount of the proved properties is amortized on the unit-of-production method. The Company’s oil and gas property represents an investment in unproved properties. These costs are excluded from the amortized cost pool until proved reserves are found or until it is determined that the costs are impaired. All costs excluded are reviewed at least quarterly to determine if impairment has occurred. The amount of any impairment is charged to expense since a reserve base has not yet been established. Impairment requiring a charge to expense may be indicated through evaluation of drilling results, relinquishing drilling rights or other information. During the fourth quarter of 2022, the Company testing protocol was concluded at the MJ-02 well. The test results confirmed that the MJ-02 well did not contain hydrocarbons in commercial quantities in the zones tested. As a result, in the year ended December 31, 2022, the Company recorded a non-cash impairment charge to its unproved oil and gas properties of $45,615,000. During the three and six months ended June 30, 2023, the Company recorded post-impairment charges of $48,000 and $93,000, respectively. During the three and six months ended June 30, 2022, the Company did not record any post-impairment charges. Currently, the Company has no economically recoverable reserves and no amortization base. The Company’s unproved oil and gas properties consist of capitalized exploration costs of $16,191,000 and $15,889,000 as of June 30, 2023 and December 31, 2022, respectively. D. Fair Value Measurements The Company follows Accounting Standards Codification (ASC) 820, “Fair Value Measurements and Disclosures,” as amended by Financial Accounting Standards Board (FASB) Financial Staff Position (FSP) No. 157 and related guidance. Those provisions relate to the Company’s financial assets and liabilities carried at fair value and the fair value disclosures related to financial assets and liabilities. ASC 820 defines fair value, expands related disclosure requirements, and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: ● Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; ● Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and ● Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. The Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities, are carried at historical cost. At June 30, 2023, and December 31, 2022, the carrying amounts of these instruments approximated their fair values because of the short-term nature of these instruments. E. Stock-Based Compensation ASC 718, “Compensation – Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the consolidated financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 718 Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of the performance commitment date or performance completion date. F. Warrants In connection with the Dividend Reinvestment and Stock Purchase Plan (“DSPP”) financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are stand-alone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued in conjunction with the issuance of common stock are initially recorded and accounted as a part of the DSPP investment as additional paid-in capital of the common stock issued. All other warrants are recorded at fair value and expensed over the requisite service period or at the date of issuance, if there is not a service period. Warrants granted in connection with ongoing arrangements are more fully described in Note 3, Stockholders’ Equity G. Related parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. All transactions with related parties are recorded at fair value of the goods or services exchanged. Zion did not have any related party transactions for the periods covered in this report. H. Recently Adopted Accounting Pronouncements In March 2020, the FASB issued ASU 2020-03, “Codification Improvements to Financial Instruments”: The amendments in this update are to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2020-03 are not expected to have a significant effect on current accounting practices. The ASU improves various financial instrument topics in the Codification to increase stakeholder awareness of the amendments and to expedite the improvement process by making the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. The ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022 with early application permitted. Zion adopted ASU 2020-03 in the first quarter of 2023. The adoption of this ASU did not have any impact on its consolidated financial statements. In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers In September 2022, the FASB issued ASU No. 2022-04 , Liabilities – Supplier Finance Programs (Subtopic 405-50) Other Recent Accounting Pronouncements The Company does not believe that the adoption of any recently issued accounting pronouncements in 2023 had a significant impact on our consolidated financial position, results of operations, or cash flow. I. Depreciation and Accounting for Drilling Rig and Related Equipment Zion purchased an onshore oil and gas drilling rig, drilling pipe, related equipment and spare parts for a purchase price of $5.6 million in cash, inclusive of approximately $540,000 allocated in spare parts and $48,000 allocated in additional separate assets. The value of the spare parts and separate assets are captured in separate ledger accounts, but reported as one line item with the drilling rig on the balance sheet. Zion determined that the life of the I-35 drilling rig (the rig Zion purchased), is 10 years. Zion is depreciating the rig on a straight-line basis. Zion uses the First In First Out (“FIFO”) method of accounting for the inventory of spare parts, meaning that the earliest items purchased will be the first item charged to the well in which the inventory of spare parts gets consumed. It is also noteworthy that various components and systems on the rig will be subject to certifications by the manufacturer to ensure that the rig is maintained at optimal levels. Per standard practice in upstream oil and gas, each certification performed on our drilling rig increases the useful life of the rig by five years. The costs of each certification will be added to the drilling rig account, and our straight-line amortization will be adjusted accordingly. See the table below for a reconciliation of the rig-related activity during the quarter ended June 30, 2023: I-35 Drilling Rig & Associated Equipment: As of June 30, 2023 I-35 Rig Other Total US$ thousands US$ thousands US$ thousands US$ thousands December 31, 2022 5,225 619 437 6,281 Asset Additions - - - - Asset Depreciation (317 ) - (63 ) (380 ) Asset Disposals for Self-Consumption - (11 ) - (11 ) June 30, 2023 4,908 608 374 5,890 During the six months ended June 30, 2023 and 2022, the Company had depreciation expense of $380,000 and $371,000, respectively. The asset disposal due to self-consumption was not material during the periods.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2023
Stockholders' Equity [Abstract]
Stockholders' Equity	Note 3 - Stockholders’ Equity The Company’s shareholders approved the amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock, par value $0.01, that the Company is authorized to issue from 800,000,000 shares to 1,200,000,000 shares, effective June 7, 2023. A. 2021 Omnibus Incentive Stock Option Plan Effective June 9, 2021, the Company’s shareholders authorized the adoption of the Zion Oil & Gas, Inc. 2021 Omnibus Incentive Stock Option Plan (“Omnibus Plan”) for employees, directors and consultants, initially reserving for issuance thereunder 38,000,000 shares of common stock. The Omnibus Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, bonus stock, awards in lieu of cash obligations, other stock-based awards and performance units. The plan also permits cash payments under certain conditions. The compensation committee of the Board of Directors (comprised of independent directors) is responsible for determining the type of award, when and to whom awards are granted, the number of shares and the terms of the awards and exercise prices. The options are exercisable for a period not to exceed ten years from the date of grant. During the six months ended June 30, 2023, the Company granted the following options from the 2021 Equity Omnibus Plan for employees, directors and consultants, to purchase shares of common stock as non-cash compensation: i. Options to purchase 175,000 shares of Common Stock to five senior officers and one staff member at an exercise price of $0.0615 per share. The options vested upon grant and are exercisable through January 4, 2033. The fair value of the options at the date of grant amounted to approximately $9,000. ii. Options to purchase 25,000 shares of Common Stock to one senior officer at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 4, 2033. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $1,500. iii. Options to purchase 25,000 shares of Common Stock to one board member, at an exercise price of $0.07 per share. The options vested upon grant and are exercisable through June 8, 2033. The fair value of the options at the date of grant amounted to approximately $1,500. During the six months ended June 30, 2022, the Company granted the following options from the 2021 Equity Omnibus Plan for employees, directors and consultants, to purchase shares of common stock as non-cash compensation: i. Options to purchase 175,000 shares of Common Stock to six senior officers and one staff member at an exercise price of $0.1529 per share. The options vested upon grant and are exercisable through January 4, 2032. The fair value of the options at the date of grant amounted to approximately $22,000. ii. Options to purchase 25,000 shares of Common Stock to one senior officer at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 4, 2032. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $4,000. iii. Options to purchase 300,000 shares of Common Stock to one senior officer and one staff member at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 5, 2032. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $39,000. iv. Options to purchase 200,000 shares of Common Stock to one board member at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 5, 2032. These options were granted per the provisions under the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $29,000. v. Options to purchase 1,600,000 shares of Common Stock to five senior officers and four staff members at an exercise price of $0.1529 per share. The options vest on January 5, 2023 (one year from the date of grant) and are exercisable through January 5, 2032. The fair value of the options at the date of grant amounted to approximately $209,000, and will be recognized during the years 2022 and 2023. vi. Options to purchase 1,400,000 shares of Common Stock to seven board members, at an exercise price of $0.1529 per share. The options vest on January 5, 2023 (one year from the date of grant) and are exercisable through January 5, 2032. The fair value of the options at the date of grant amounted to approximately $182,000, and will be recognized during the years 2022 and 2023. vii. Options to purchase 160,000 shares of Common Stock to four staff members, at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 17, 2032. These options were granted per the provisions under the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $23,000. viii. Options to purchase 200,000 shares of Common Stock to six staff members at an exercise price of $0.14 per share. The options vest on January 17, 2023 (one year from the date of grant) and are exercisable through January 17, 2032. The fair value of the options at the date of grant amounted to approximately $26,000, and will be recognized during the years 2022 and 2023. ix. Options to purchase 40,000 shares of Common Stock to two consultants at an exercise price of $0.14 per share. The options vest on January 17, 2023 (one year from the date of grant) and are exercisable through January 17, 2032. The fair value of the options at the date of grant amounted to approximately $5,000, and will be recognized during the years 2022 and 2023. x. Options to purchase 25,000 shares of Common Stock to one board member, at an exercise price of $0.11 per share. The options vested upon grant and are exercisable through April 1, 2032. The fair value of the options at the date of grant amounted to approximately $2,000. xi. Options to purchase 3,210,000 shares of Common Stock to five senior officers, two consultants and ten staff members at an exercise price of $0.15 per share. The options vested on April 15, 2023 (in one year) and are exercisable through April 15, 2032. The fair value of the options at the date of grant amounted to approximately $394,000, and will be recognized during the years 2022 and 2023. xii. Options to purchase 1,090,000 shares of Common Stock to one senior officer, one board member and five staff members at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through April 15, 2032. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $149,000. xiii. Options to purchase 3,200,000 shares of Common Stock to eight board members at an exercise price of $0.15 per share. The options vested on April 15, 2023 (in one year) and are exercisable through April 15, 2023. The fair value of the options at the date of grant amounted to approximately $393,000. B. Stock Options The stock option transactions since January 1, 2023 are shown in the table below: Number of Weighted US$ Outstanding, December 31, 2022 26,391,250 0.30 Changes during 2023 to: Granted to employees, officers, directors and others 225,000 0.06 Expired/Cancelled/Forfeited (25,000 ) 1.33 Exercised (150,000 ) 0.07 Outstanding, June 30, 2023 26,441,250 0.30 Exercisable, June 30, 2023 21,286,250 0.32 The following table summarizes information about stock options outstanding as of June 30, 2023: Shares underlying outstanding options (non-vested) Shares underlying outstanding options (fully vested) Range of Number Weighted Weighted Range of Number Weighted Weighted US$ US$ US$ US$ 0.18 5,155,000 9.24 0.18 0.01 10,000 0.37 0.01 — — — — 0.01 5,000 0.95 0.01 — — — — 0.01 20,000 2.93 0.01 — — — — 0.01 130,000 3.51 0.01 — — — — 0.01 50,000 3.52 0.01 — — — — 0.01 60,000 3.80 0.01 — — — — 0.01 200,000 3.89 0.01 — — — — 0.01 40,000 4.26 0.01 — — — — 0.01 70,000 4.51 0.01 — — — — 0.01 25,000 4.52 0.01 — — — — 0.01 30,000 4.67 0.01 — — — — 0.01 4,000 4.77 0.01 — — — — 0.01 25,000 5.53 0.01 — — — — 0.01 35,000 6.22 0.01 — — — — 0.01 150,000 6.39 0.01 — — — — 0.01 35,000 6.52 0.01 — — — — 0.01 75,000 7.52 0.01 — — — — 0.01 200,000 7.90 0.01 — — — — 0.01 300,000 8.05 0.01 — — — — 0.01 10,000 8.18 0.01 — — — — 0.01 500,000 8.52 0.01 — — — — 0.01 55,000 8.56 0.01 — — — — 0.01 960,000 8.80 0.01 — — — — 0.01 75,000 9.13 0.01 — — — — 0.01 10,000 9.18 0.01 — — — — 0.01 795,000 9.24 0.01 — — — — 0.01 25,000 9.52 0.01 — — — — 0.06 50,000 9.52 0.06 — — — — 0.07 25,000 9.95 0.07 — — — — 0.14 240,000 8.56 0.14 — — — — 0.15 3,200,000 8.52 0.15 — — — — 0.15 6,410,000 8.80 0.15 — — — — 0.16 340,000 2.45 0.16 — — — — 0.16 75,000 6.45 0.16 — — — — 0.18 25,000 2.43 0.18 — — — — 0.24 25,000 9.10 0.24 — — — — 0.24 118,000 9.13 0.24 — — — — 0.25 50,000 8.18 0.25 — — — — 0.25 363,000 8.18 0.25 — — — — 0.28 25,000 2.18 0.28 — — — — 0.28 25,000 6.18 0.28 — — — — 0.29 25,000 3.96 0.29 — — — — 0.39 1,435,000 8.03 0.39 — — — — 0.59 1,400,000 3.89 0.59 — — — — 0.59 1,600,000 7.90 0.59 — — — — 0.92 350,000 3.52 0.92 — — — — 0.92 550,000 7.52 0.92 — — — — 1.38 105,307 1.51 1.38 — — — — 1.67 405,943 1.26 1.67 — — — — 1.75 250,000 0.02 1.75 — — — — 1.78 25,000 1.18 1.78 — — — — 2.31 250,000 0.51 2.31 — — — — 4.15 25,000 1.01 4.15 0.18 5,155,000 0.18 0.01-4.15 21,286,250 0.32 Granted to employees The following table sets forth information about the weighted-average fair value of options granted to employees and directors during the year, using the Black Scholes option-pricing model and the weighted-average assumptions used for such grants: For the 2023 2022 Weighted-average fair value of underlying stock at grant date $ 0.06 $ 0.14 Dividend yields — — Expected volatility 136%-137 % 127%-135 % Risk-free interest rates 3.87%-3.85 % 1.37%-2.79 % Expected lives (in years) 5.00 5.00-5.50 Weighted-average grant date fair value $ 0.06 $ 0.13 Granted to non-employees The following table sets forth information about the weighted-average fair value of options granted to non-employees during the year, using the Black Scholes option-pricing model and the weighted-average assumptions used for such grants: For the 2023 2022 Weighted-average fair value of underlying stock at grant date — $ 0.14 Dividend yields — — Expected volatility — % 103% - 104 % Risk-free interest rates — % 1.78% - 2.83 % Expected lives (in years) — 10 Weighted-average grant date fair value — $ 0.13 There were no warrants or options granted to non-employees for the six months ended June 30, 2023. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the options. The expected life represents the weighted average period of time that options granted are expected to be outstanding. The expected life of the options granted to employees and directors is calculated based on the Simplified Method as allowed under Staff Accounting Bulletin No. 110 (“SAB 110”), giving consideration to the contractual term of the options and their vesting schedules, as the Company does not have sufficient historical exercise data at this time. The expected life of the option granted to non-employees equals their contractual term. In the case of an extension of the option life, the calculation was made on the basis of the extended life. C. Compensation Cost for Warrant and Option Issuances The following table sets forth information about the compensation cost of warrant and option issuances recognized for employees and directors: For the three months ended June 30, 2023 2022 US$ thousands US$ thousands 242 417 The following table sets forth information about the compensation cost of warrant and option issuances recognized for non-employees: For the six months ended June 30, 2023 2022 US$ thousands US$ thousands 656 631 The following table sets forth information about the compensation cost of option issuances recognized for employees and non-employees and capitalized to Unproved Oil & Gas properties: For the three months ended June 30, 2023 2022 US$ thousands US$ thousands — 3 For the six months ended June 30, 2023 2022 US$ thousands US$ thousands 2 4 The following table sets forth information about the compensation cost of option issuances recognized for employees and non-employees and capitalized to Unproved Oil & Gas properties: For the three months ended June 30, 2023 2022 US$ thousands US$ thousands — 10 For the six months ended June 30, 2023 2022 US$ thousands US$ thousands — 17 As of June 30, 2023, there was $194,000 of unrecognized compensation cost related to non-vested stock options granted under the Company’s various stock option plans. That cost is expected to be recognized during 2023. D. Dividend Reinvestment and Stock Purchase Plan (“DSPP”) On March 13, 2014 Zion filed a registration statement on Form S-3 that was part of a replacement registration statement that was filed with the SEC using a “shelf” registration process. The registration statement was declared effective by the SEC on March 31, 2014. On February 23, 2017, the Company filed a Form S-3 with the SEC (Registration No. 333-216191) as a replacement for the Form S-3 (Registration No. 333-193336), for which the three year period ended March 31, 2017, along with the base Prospectus and Supplemental Prospectus. The Form S-3, as amended, and the new base Prospectus became effective on March 10, 2017, along with the Prospectus Supplement that was filed and became effective on March 10, 2017. The Prospectus Supplement under Registration No. 333-216191 describes the terms of the DSPP and replaces the prior Prospectus Supplement, as amended, under the prior Registration No. 333-193336. On March 27, 2014, we launched our Dividend Reinvestment and Stock Purchase Plan (the “DSPP”) pursuant to which stockholders and interested investors can purchase shares of the Company’s Common Stock as well as units of the Company’s securities directly from the Company. The terms of the DSPP are described in the Prospectus Supplement originally filed on March 31, 2014 (the “Original Prospectus Supplement”) with the Securities and Exchange Commission (“SEC”) under the Company’s effective registration Statement on Form S-3, as thereafter amended. On January 13, 2015, the Company amended the Original Prospectus Supplement (“Amendment No. 3”) to provide for a unit option (the “Unit Option”) under the DSPP comprised of one share of Common Stock and three Common Stock purchase warrants with each unit priced at $4.00. Each warrant afforded the participant the opportunity to purchase the Company’s Common Stock at a warrant exercise price of $1.00. Each of the three warrants series had different expiration dates that had been extended. The ZNWAB warrants first became exercisable on May 2, 2016 and, in the case of ZNWAC on May 2, 2017 and in the case of ZNWAD on May 2, 2018, at a per share exercise price of $1.00. As of May 2, 2017, any outstanding ZNWAB warrants expired. As of May 2, 2018, any outstanding ZNWAC warrants expired. On May 29, 2019, the Company extended the termination date of the ZNWAD Warrant by one (1) year from the expiration date of May 2, 2020 to May 2, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAD Warrant by two (2) years from the expiration date of May 2, 2021 to May 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. As of May 2, 2023, any outstanding ZNWAD warrants expired. On November 1, 2016, the Company launched a unit offering under the Company’s DSPP pursuant to which participants could purchase units comprised of seven shares of Common Stock and seven Common Stock purchase warrants, at a per unit purchase price of $10. The warrant is referred to as “ZNWAE.” The ZNWAE warrants became exercisable on May 1, 2017 and continued to be exercisable through May 1, 2020 at a per share exercise price of $1.00. On May 29, 2019, the Company extended the termination date of the ZNWAE Warrant by one (1) year from the expiration date of May 1, 2020 to May 1, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAE Warrant by two (2) years from the expiration date of May 1, 2021 to May 1, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share at the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company may, in its sole discretion, accelerate the termination of the warrant upon providing 60 days advanced notice to the warrant holders. As of May 1, 2023, any outstanding ZNWAE warrants expired. On May 22, 2017, the Company launched a new unit offering. This unit offering consisted of a new combination of common stock and warrants, a new time period in which to purchase under the program, and a new unit price, but otherwise the same unit program features, conditions and terms in the Prospectus Supplement applied. The unit offering terminated on July 12, 2017. This program enabled participants to purchase Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 25 shares of Common Stock at a warrant exercise price of $1.00 per share. The warrant is referred to as “ZNWAF.” All ZNWAF warrants became exercisable on August 14, 2017 and continued to be exercisable through August 14, 2020 at a per share exercise price of $1.00. On May 29, 2019, the Company extended the termination date of the ZNWAF Warrant by one (1) year from the expiration date of August 14, 2020 to August 14, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAF Warrant by two (2) years from the expiration date of August 14, 2021 to August 14, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share as the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company has the sole discretion to accelerate the termination date of the warrant upon providing 60 days advanced notice to the warrant holders. An Amendment No. 2 to the Prospectus Supplement (as described below) was filed on October 12, 2017. Under Amendment No. 2, the Company initiated another unit offering which terminated on December 6, 2017. This unit offering enabled participants to purchase Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s Common Stock as reported on the NASDAQ on the unit purchase date and (ii) Common Stock purchase warrants to purchase an additional 15 shares of Common Stock at a warrant exercise price of $1.00 per share. The warrant is referred to as “ZNWAG.” The warrants became exercisable on January 8, 2018 and continue to be exercisable through January 8, 2024 at a revised per share exercise price of $.25. The warrant terms provide that if the Company’s Common Stock trades above $5.00 per share as the closing price for 15 consecutive trading days at any time prior to the expiration date of the warrant, the Company has the sole discretion to accelerate the termination date of the warrant upon providing 60 days advanced notice to the warrant holders. On December 14, 2022, the Company extended the termination date of the ZNWAG warrant by one (1) year from the expiration date of January 8, 2023 to January 8, 2024. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On February 1, 2018, the Company launched another unit offering which terminated on February 28, 2018. The unit offering consisted of Units of our securities where each Unit (priced at $250.00 each) was comprised of (i) 50 shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional 50 shares of Common Stock. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of $5.00. The warrant is referred to as “ZNWAH.” The warrants became exercisable on April 2, 2018 and continued to be exercisable through April 2, 2020 at a per share exercise price of $5.00, after the Company, on December 4, 2018, extended the termination date of the Warrant by one (1) year from the expiration date of April 2, 2019 to April 2, 2020. On May 29, 2019, the Company extended the termination date of the ZNWAH Warrant by one (1) year from the expiration date of April 2, 2020 to April 2, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAH Warrant by two (2) years from the expiration date of April 2, 2021 to April 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. As of April 2, 2023, any outstanding ZNWAH warrants expired. On August 21, 2018, the Company initiated another unit offering, and it terminated on September 26, 2018. The offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s publicly traded common stock as reported on the NASDAQ on the Unit Purchase Date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock acquired under the Units purchased. Each warrant affords the investor the opportunity to purchase one share of Company Common Stock at a warrant exercise price of $1.00. The warrant is referred to as “ZNWAJ.” The warrants became exercisable on October 29, 2018 and continued to be exercisable through October 29, 2020 at a per share exercise price of $ On May 29, 2019, the Company extended the termination date of the ZNWAJ Warrant by one (1) year from the expiration date of October 29, 2020 to October 29, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAJ Warrant by two (2) years from the expiration date of October 29, 2021 to October 29, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On December 10, 2018, the Company initiated another unit offering, and it terminated on January 23, 2019. The offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional two hundred and fifty (250) shares of Common Stock at a per share exercise price of $0.01. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that are acquired under the Units purchased. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $0.01. The warrant is referred to as “ZNWAK.” The warrants became exercisable on February 25, 2019 and continued to be exercisable through February 25, 2020 at a per share exercise price of $0.01. On May 29, 2019, the Company extended the termination date of the ZNWAK Warrant by one (1) year from the expiration date of February 25, 2020 to February 25, 2021. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On September 15, 2020, the Company extended the termination date of the ZNWAK Warrant by two (2) years from the expiration date of February 25, 2021 to February 25, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. As of February 25, 2023, any outstanding ZNWAK warrants expired. On April 24, 2019, the Company initiated another unit offering and it terminated on June 26, 2019, after the Company, on June 5, 2019, extended the termination date of the unit offering. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $2.00. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the Unit Program with the purchase of at least one Unit and also enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional twenty-five (25) warrants at an exercise price of $2.00 during this Unit Option Program. The twenty-five (25) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were entitled to the additional twenty-five (25) warrants once, if they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $2.00. The warrant is referred to as “ZNWAL.” The warrants became exercisable on August 26, 2019 and continued to be exercisable through August 26, 2021 at a per share exercise price of $2.00. On September 15, 2020, the Company extended the termination date of the ZNWAL Warrant by two (2) years from the expiration date of August 26, 2021 to August 26, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. Under our Plan, the Company under a Request For Waiver Program executed Waiver Term Sheets of a unit option program consisting of a Unit (shares of stock and warrants) of its securities and subsequently an option program consisting of shares of stock to a participant. The participant’s Plan account was credited with the number of shares of the Company’s Common Stock and warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant shall have the company notation of “ZNWAM.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants became exercisable on January 15, 2021 and continue to be exercisable through July 15, 2023 at a revised per share exercise price of $.05. On March 21, 2022, the Company extended the termination date of the ZNWAM warrant by one (1) year from the expiration date of July 15, 2022 to July 15, 2023 and revised the exercise price to $0.05. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On June 16, 2023, the Company extended the termination date of the ZNWAM warrant from July 15, 2023 to September 6, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On February 1, 2021, the Company initiated a unit offering and it terminated on March 17, 2021. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional twenty-five (25) shares of Common Stock at a per share exercise price of $1.00. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the Unit Program with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional ten (10) warrants at an exercise price of $1.00 during this Unit Option Program. The ten (10) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were also entitled to the additional ten (10) warrants once, provided that they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant is referred to as “ZNWAN.” The warrants became exercisable on May 16, 2021 and continued to be exercisable through May 16, 2023 at a per share exercise price of $1.00. As of May 16, 2023, any outstanding ZNWAN warrants expired. On April 12, 2021, the Company initiated a unit offering and it terminated on May 12, 2021. The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $.25. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the unit offering with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional fifty (50) warrants at an exercise price of $.25 during this Unit Option Program. The fifty (50) additional warrants were for enrolling into the AMI program. Existing subscribers to the AMI were also entitled to the additional fifty (50) warrants once, provided that they purchased at least one (1) unit during the Unit program. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant is referred to as “ZNWAO.” The warrants became exercisable on June 12, 2021 and continued to be exercisable through June 12, 2023 at a per share exercise price of $.25. As of June 12, 2023, any outstanding ZNWAO warrants expired. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet for a program consisting of Zion securities to a participant. After conclusion of the program on June 17, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on June 18, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock a

Unproved Oil and Gas Properties

Unproved Oil and Gas Properties, Full Cost Method	6 Months Ended
	Jun. 30, 2023
Unproved Oil and Gas Properties, Full Cost Method [Abstract]
Unproved Oil and Gas Properties, Full Cost Method	Note 4 - Unproved Oil and Gas Properties, Full Cost Method Unproved oil and gas properties, under the full cost method, are comprised as follows: June 30, December 31, US$ US$ Excluded from amortization base: Drilling costs, and other operational related costs 2,452 2,362 Capitalized salary costs 2,394 2,342 Capitalized interest costs 1,418 1,418 Legal and seismic costs, license fees and other preparation costs 9,888 9,728 Other costs 39 39 16,191 15,889 Post Impairment of unproved oil and gas properties comprised as follows: For the three months ended For the six months ended 2023 2022 2023 2022 US$ US$ US$ US$ Excluded from amortization base: Drilling costs, and other operational related costs 44 - 55 - Capitalized salary costs - - - - Capitalized interest costs - - - - Legal costs, license fees and other preparation costs 4 - 38 - Other costs - - - - 48 - 93 - Changes in Unproved oil and gas properties during the three and six months ended June 30, 2023 and 2022 are as follows: For the three months ended For the six months ended 2023 2022 2023 2022 US$ US$ US$ US$ Excluded from amortization base: Drilling costs, and other operational related costs 82 4,735 145 5,363 Capitalized salary costs 26 69 52 121 Capitalized interest costs - - - - Legal costs, license fees and other preparation costs 74 347 198 816 Other costs - - - - Impairment of unproved oil and gas properties (48 ) - (93 ) - *134 *5,151 *302 *6,300 * Inclusive of non-cash amounts of approximately $709,000, and $571,000 during the three months ended June 30, 2023, and 2022, respectively * Inclusive of non-cash amounts of approximately $806,000, and $1,708,000 during the six months ended June 30, 2023, and 2022, respectively Please refer to Footnote 1 – Nature of Operations and Going Concern for more information about Zion’s exploration activities.

Right of Use Lease Assets and L

Right of Use Lease Assets and Lease Obligations	6 Months Ended
	Jun. 30, 2023
Right of Use Lease Assets and Lease Obligations [Abstract]
Right of use lease assets and lease obligations	Note 5 - Right of use lease assets and lease obligations The Company is a lessee in several non-cancellable operating leases for transportation and office space. The table below presents the operating lease assets and liabilities recognized on the balance sheet as of June 30, 2023 and December 31, 2022: June 30, December 31, US$ US$ Operating lease assets $ 79 $ 202 Operating lease liabilities: Current operating lease liabilities $ 67 $ 196 Non-current operating lease liabilities $ 12 $ 12 Total operating lease liabilities $ 79 $ 208 The depreciable lives of operating lease assets and leasehold improvements are limited by the expected lease term. The Company’s leases generally do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease within a particular currency environment. The Company used incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date. The Company’s weighted average remaining lease term and weighted average discount rate for operating leases as of June 30, 2023 are: June 30, Weighted average remaining lease term (years) 0.6 Weighted average discount rate 4.9 % The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under non-cancellable operating leases with terms of more than one year to the total operating lease liabilities recognized on the condensed balance sheets as of June 30, 2023: US$ 2023 68 2024 11 2025 - 2026 - Thereafter - Total undiscounted future minimum lease payments 79 Less: portion representing imputed interest (1 ) Total undiscounted future minimum lease payments 78 Operating lease costs were $57,000 and $126,000 for the three and six months ended June 30, 2023, respectively. Operating lease costs were $68,000 and $137,000 for the three and six months ended June 30, 2022, respectively. Operating lease costs are included within general and administrative expenses on the statements of operations. Cash paid for amounts included in the measurement of operating lease liabilities was $57,000 and $127,000 for the three and six months ended June 30, 2023, respectively. Cash paid for amounts included in the measurement of operating lease liabilities was $71,000 and $143,000 for the three and six months ended June 30, 2022, respectively These amounts are included in operating activities in the statements of cash flows. Right-of-use assets obtained in exchange for new operating lease liabilities were $ nil nil Right-of-use assets obtained in exchange for new operating lease liabilities were $136,000 and $136,000 for the three and six months ended June 30, 2022, respectively.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 6 - Commitments and Contingencies A. Securities and Exchange Commission (“SEC”) Investigation As previously disclosed by the Company, on June 21, 2018, the Fort Worth Regional Office of the SEC informed Zion that it was conducting a formal, non-public investigation and asked that we provide certain information and documents in connection with its investigation, which we did. On April 5, 2023, the Company received from the Fort Worth Regional Office of the SEC written notice to the Company concluding the investigation as to the Company and that the SEC does “not intend to recommend an enforcement action by the Commission against Zion.” B. Litigation From time to time, the Company may be subject to routine litigation, claims or disputes in the ordinary course of business. The Company defends itself vigorously in all such matters. However, we cannot predict the outcome or effect of any of the potential litigation, claims or disputes. The Company is not subject to any litigation at the present time. C. Market Conditions – Coronavirus Pandemic During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (“COVID-19”). The pandemic significantly impacted the economic conditions in the United States and Israel, as federal, state and local governments reacted to the public health crisis, creating significant uncertainties in the United States, Israel and world economies. In the interest of public health and safety, jurisdictions (international, national, state and local) where we have operations, restricted travel and required workforces to work from home. However, as of the date of this report, most of our employees are working at our physical offices, but have the ability to work from home as needed. While there are various uncertainties to navigate, the Company’s business activities are continuing. The situation is rapidly changing and additional impacts to the business may arise that we are not aware of currently. We cannot predict whether, when or the manner in which the conditions surrounding COVID-19 will change including the timing of lifting any restrictions or work from home arrangements. The full extent of COVID-19’s impact on our operations and financial performance depends on future developments that are uncertain and unpredictable, including the duration and spread of the pandemic, its impact on capital and financial markets and any new information that may emerge concerning the severity of the virus, its spread to other regions as well as the actions taken to contain it, among others. D. Environmental and Onshore Licensing Regulatory Matters The Company is engaged in oil and gas exploration and production and may become subject to certain liabilities as they relate to environmental clean-up of well sites or other environmental restoration procedures and other obligations as they relate to the drilling of oil and gas wells or the operation thereof. Various guidelines have been published in Israel by the State of Israel’s Petroleum Commissioner and Energy and Environmental Ministries as it pertains to oil and gas activities. Mention of these older guidelines was included in previous Zion filings. The Company believes that these regulations will result in an increase in the expenditures associated with obtaining new exploration rights and drilling new wells. The Company expects that an additional financial burden could occur as a result of requiring cash reserves that could otherwise be used for operational purposes. In addition, these regulations are likely to continue to increase the time needed to obtain all of the necessary authorizations and approvals to drill and production test exploration wells. As of June 30, 2023, and December 31, 2022, the Company accrued $ nil nil E. Bank Guarantees As of June 30, 2023, the Company provided Israeli-required bank guarantees to various governmental bodies (approximately $930,000) and others (approximately $88,000) with respect to its drilling operation in an aggregate amount of approximately $1,018,000. The (cash) funds backing these guarantees are held in restricted interest-bearing accounts in Israel and are reported on the Company’s balance sheets as fixed short-term bank deposits – restricted. F. Risks Market risk is a broad term for the risk of economic loss due to adverse changes in the fair value of a financial instrument. These changes may be the result of various factors, including interest rates, foreign exchange rates, commodity prices and/or equity prices. In the normal course of doing business, we are exposed to the risks associated with foreign currency exchange rates and changes in interest rates. Foreign Currency Exchange Rate Risks. Interest Rate Risk. The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest our excess cash in short-term bank deposits and money market funds that may invest in high quality debt instruments.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 7 - Subsequent Events (i) Approximately $921,000 was collected through the Company’s DSPP program during the period July 1 through August 8, 2023.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Summary of Significant Accounting Policies [Abstract]
Net Loss per Share Data	A. Net Loss per Share Data Basic and diluted net loss per share of common stock, par value $0.01 per share (“Common Stock”) is presented in conformity with ASC 260-10 “Earnings Per Share.” Diluted net loss per share is the same as basic net loss per share as the inclusion of 56,933,841 and 56,876,638 and 37,061,435 and 34,216,856 Common Stock equivalents in the three and six-month period ended June 30, 2023 and 2022 respectively, would be anti-dilutive.
Use of Estimates	B. Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of expenses. Such estimates include the valuation of unproved oil and gas properties, deferred tax assets, asset retirement obligations, borrowing rate of interest consideration for leases accounting and legal contingencies. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity, foreign currency, and energy markets have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the consolidated financial statements in future periods. The full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international markets. We have made estimates of the impact of COVID-19 within our consolidated financial statements, and although there is currently no major impact, there may be changes to those estimates in future periods. Actual results may differ from these estimates.
Oil and Gas Properties and Impairment	C. Oil and Gas Properties and Impairment The Company follows the full-cost method of accounting for oil and gas properties. Accordingly, all costs associated with acquisition, exploration and development of oil and gas reserves, including directly related overhead costs, are capitalized. All capitalized costs of oil and gas properties, including the estimated future costs to develop proved reserves, are amortized on the unit-of-production method using estimates of proved reserves. Investments in unproved properties and major development projects are not amortized until proved reserves associated with the projects can be determined or until impairment occurs. If the results of an assessment indicate that the properties are impaired, the amount of the impairment is included in loss from continuing operations before income taxes, and the adjusted carrying amount of the proved properties is amortized on the unit-of-production method. The Company’s oil and gas property represents an investment in unproved properties. These costs are excluded from the amortized cost pool until proved reserves are found or until it is determined that the costs are impaired. All costs excluded are reviewed at least quarterly to determine if impairment has occurred. The amount of any impairment is charged to expense since a reserve base has not yet been established. Impairment requiring a charge to expense may be indicated through evaluation of drilling results, relinquishing drilling rights or other information. During the fourth quarter of 2022, the Company testing protocol was concluded at the MJ-02 well. The test results confirmed that the MJ-02 well did not contain hydrocarbons in commercial quantities in the zones tested. As a result, in the year ended December 31, 2022, the Company recorded a non-cash impairment charge to its unproved oil and gas properties of $45,615,000. During the three and six months ended June 30, 2023, the Company recorded post-impairment charges of $48,000 and $93,000, respectively. During the three and six months ended June 30, 2022, the Company did not record any post-impairment charges. Currently, the Company has no economically recoverable reserves and no amortization base. The Company’s unproved oil and gas properties consist of capitalized exploration costs of $16,191,000 and $15,889,000 as of June 30, 2023 and December 31, 2022, respectively.
Fair Value Measurements	D. Fair Value Measurements The Company follows Accounting Standards Codification (ASC) 820, “Fair Value Measurements and Disclosures,” as amended by Financial Accounting Standards Board (FASB) Financial Staff Position (FSP) No. 157 and related guidance. Those provisions relate to the Company’s financial assets and liabilities carried at fair value and the fair value disclosures related to financial assets and liabilities. ASC 820 defines fair value, expands related disclosure requirements, and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: ● Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; ● Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and ● Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. The Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities, are carried at historical cost. At June 30, 2023, and December 31, 2022, the carrying amounts of these instruments approximated their fair values because of the short-term nature of these instruments.
Stock-Based Compensation	E. Stock-Based Compensation ASC 718, “Compensation – Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the consolidated financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 718 Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of the performance commitment date or performance completion date.
Warrants	F. Warrants In connection with the Dividend Reinvestment and Stock Purchase Plan (“DSPP”) financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are stand-alone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued in conjunction with the issuance of common stock are initially recorded and accounted as a part of the DSPP investment as additional paid-in capital of the common stock issued. All other warrants are recorded at fair value and expensed over the requisite service period or at the date of issuance, if there is not a service period. Warrants granted in connection with ongoing arrangements are more fully described in Note 3, Stockholders’ Equity
Related parties	G. Related parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. All transactions with related parties are recorded at fair value of the goods or services exchanged. Zion did not have any related party transactions for the periods covered in this report.
Recently Adopted Accounting Pronouncements	H. Recently Adopted Accounting Pronouncements In March 2020, the FASB issued ASU 2020-03, “Codification Improvements to Financial Instruments”: The amendments in this update are to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2020-03 are not expected to have a significant effect on current accounting practices. The ASU improves various financial instrument topics in the Codification to increase stakeholder awareness of the amendments and to expedite the improvement process by making the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. The ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022 with early application permitted. Zion adopted ASU 2020-03 in the first quarter of 2023. The adoption of this ASU did not have any impact on its consolidated financial statements. In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers In September 2022, the FASB issued ASU No. 2022-04 , Liabilities – Supplier Finance Programs (Subtopic 405-50) Other Recent Accounting Pronouncements The Company does not believe that the adoption of any recently issued accounting pronouncements in 2023 had a significant impact on our consolidated financial position, results of operations, or cash flow.
Depreciation and Accounting for Drilling Rig and Related Equipment	I. Depreciation and Accounting for Drilling Rig and Related Equipment Zion purchased an onshore oil and gas drilling rig, drilling pipe, related equipment and spare parts for a purchase price of $5.6 million in cash, inclusive of approximately $540,000 allocated in spare parts and $48,000 allocated in additional separate assets. The value of the spare parts and separate assets are captured in separate ledger accounts, but reported as one line item with the drilling rig on the balance sheet. Zion determined that the life of the I-35 drilling rig (the rig Zion purchased), is 10 years. Zion is depreciating the rig on a straight-line basis. Zion uses the First In First Out (“FIFO”) method of accounting for the inventory of spare parts, meaning that the earliest items purchased will be the first item charged to the well in which the inventory of spare parts gets consumed. It is also noteworthy that various components and systems on the rig will be subject to certifications by the manufacturer to ensure that the rig is maintained at optimal levels. Per standard practice in upstream oil and gas, each certification performed on our drilling rig increases the useful life of the rig by five years. The costs of each certification will be added to the drilling rig account, and our straight-line amortization will be adjusted accordingly. See the table below for a reconciliation of the rig-related activity during the quarter ended June 30, 2023: I-35 Drilling Rig & Associated Equipment: As of June 30, 2023 I-35 Rig Other Total US$ thousands US$ thousands US$ thousands US$ thousands December 31, 2022 5,225 619 437 6,281 Asset Additions - - - - Asset Depreciation (317 ) - (63 ) (380 ) Asset Disposals for Self-Consumption - (11 ) - (11 ) June 30, 2023 4,908 608 374 5,890 During the six months ended June 30, 2023 and 2022, the Company had depreciation expense of $380,000 and $371,000, respectively. The asset disposal due to self-consumption was not material during the periods.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2023
Summary of Significant Accounting Policies [Abstract]
Schedule of drilling rig & associated equipment	See the table below for a reconciliation of the rig-related activity during the quarter ended June 30, 2023 As of June 30, 2023 I-35 Rig Other Total US$ thousands US$ thousands US$ thousands US$ thousands December 31, 2022 5,225 619 437 6,281 Asset Additions - - - - Asset Depreciation (317 ) - (63 ) (380 ) Asset Disposals for Self-Consumption - (11 ) - (11 ) June 30, 2023 4,908 608 374 5,890

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2023
Stockholders' Equity (Tables) [Line Items]
Schedule of stock option transactions	The stock option transactions since January 1, 2023 are shown in the table below: Number of Weighted US$ Outstanding, December 31, 2022 26,391,250 0.30 Changes during 2023 to: Granted to employees, officers, directors and others 225,000 0.06 Expired/Cancelled/Forfeited (25,000 ) 1.33 Exercised (150,000 ) 0.07 Outstanding, June 30, 2023 26,441,250 0.30 Exercisable, June 30, 2023 21,286,250 0.32
Schedule of stock options outstanding	The following table summarizes information about stock options outstanding as of June 30, 2023: Shares underlying outstanding options (non-vested) Shares underlying outstanding options (fully vested) Range of Number Weighted Weighted Range of Number Weighted Weighted US$ US$ US$ US$ 0.18 5,155,000 9.24 0.18 0.01 10,000 0.37 0.01 — — — — 0.01 5,000 0.95 0.01 — — — — 0.01 20,000 2.93 0.01 — — — — 0.01 130,000 3.51 0.01 — — — — 0.01 50,000 3.52 0.01 — — — — 0.01 60,000 3.80 0.01 — — — — 0.01 200,000 3.89 0.01 — — — — 0.01 40,000 4.26 0.01 — — — — 0.01 70,000 4.51 0.01 — — — — 0.01 25,000 4.52 0.01 — — — — 0.01 30,000 4.67 0.01 — — — — 0.01 4,000 4.77 0.01 — — — — 0.01 25,000 5.53 0.01 — — — — 0.01 35,000 6.22 0.01 — — — — 0.01 150,000 6.39 0.01 — — — — 0.01 35,000 6.52 0.01 — — — — 0.01 75,000 7.52 0.01 — — — — 0.01 200,000 7.90 0.01 — — — — 0.01 300,000 8.05 0.01 — — — — 0.01 10,000 8.18 0.01 — — — — 0.01 500,000 8.52 0.01 — — — — 0.01 55,000 8.56 0.01 — — — — 0.01 960,000 8.80 0.01 — — — — 0.01 75,000 9.13 0.01 — — — — 0.01 10,000 9.18 0.01 — — — — 0.01 795,000 9.24 0.01 — — — — 0.01 25,000 9.52 0.01 — — — — 0.06 50,000 9.52 0.06 — — — — 0.07 25,000 9.95 0.07 — — — — 0.14 240,000 8.56 0.14 — — — — 0.15 3,200,000 8.52 0.15 — — — — 0.15 6,410,000 8.80 0.15 — — — — 0.16 340,000 2.45 0.16 — — — — 0.16 75,000 6.45 0.16 — — — — 0.18 25,000 2.43 0.18 — — — — 0.24 25,000 9.10 0.24 — — — — 0.24 118,000 9.13 0.24 — — — — 0.25 50,000 8.18 0.25 — — — — 0.25 363,000 8.18 0.25 — — — — 0.28 25,000 2.18 0.28 — — — — 0.28 25,000 6.18 0.28 — — — — 0.29 25,000 3.96 0.29 — — — — 0.39 1,435,000 8.03 0.39 — — — — 0.59 1,400,000 3.89 0.59 — — — — 0.59 1,600,000 7.90 0.59 — — — — 0.92 350,000 3.52 0.92 — — — — 0.92 550,000 7.52 0.92 — — — — 1.38 105,307 1.51 1.38 — — — — 1.67 405,943 1.26 1.67 — — — — 1.75 250,000 0.02 1.75 — — — — 1.78 25,000 1.18 1.78 — — — — 2.31 250,000 0.51 2.31 — — — — 4.15 25,000 1.01 4.15 0.18 5,155,000 0.18 0.01-4.15 21,286,250 0.32
Schedule of the compensation cost of warrant and option issuances	The following table sets forth information about the compensation cost of warrant and option issuances recognized for employees and directors: For the three months ended June 30, 2023 2022 US$ thousands US$ thousands 242 417 For the six months ended June 30, 2023 2022 US$ thousands US$ thousands 656 631 For the three months ended June 30, 2023 2022 US$ thousands US$ thousands — 3 For the six months ended June 30, 2023 2022 US$ thousands US$ thousands 2 4 For the three months ended June 30, 2023 2022 US$ thousands US$ thousands — 10 For the six months ended June 30, 2023 2022 US$ thousands US$ thousands — 17
Schedule of warrants transactions	The price and the expiration dates for the series of warrants to investors are shown in the table below. The listing contains only those warrants with a future expiration date. Period of Grant US$ Expiration Date ZNWAA Warrants B,C,F March 2013 – December 2014 2.00 January 31, 2024 ZNWAF Warrants A,B,C May 2017 – July 2017 1.00 August 14, 2023 ZNWAG Warrants C,F October 2017 – December 2017 1.00 January 08, 2024 ZNWAJ Warrants B,C August 2018 – September 2018 1.00 October 29, 2023 ZNWAL Warrants C July 2019 – August 2019 2.00 August 26, 2023 ZNWAM Warrants D,G January 2021 – March 2021 0.05 September 6, 2023 ZNWAQ Warrants D,G June 2021 0.05 September 6, 2023 ZNWAS Warrants E August 2021 – March 2022 0.25 December 31, 2025 ZNWAT Warrants E August – September 2022 0.25 December 31, 2025 ZNWAU Warrants E October – November 2022 0.25 December 31, 2025 ZNWAY Warrants H March – April 2023 0.05 Sept 10, 2023 ZNWAZ Warrants I May – June 2023 .25 July 17, 2024 A On December 4, 2018, the Company extended the expiration date of the Warrants by one (1) year. B On May 29, 2019, the Company extended the expiration date of the Warrants by one (1) year. C On September 15, 2020, the Company extended the expiration date of the Warrants by two (2) years. D On March 21, 2022, the Company extended the expiration date of the Warrants by one (1) year. On June 16, 2023, the Company extended the expiration date of the Warrants to September 6, 2023. E These warrants will be issued and become exercisable beginning on November 15, 2025 and expire on December 31, 2025. F On December 14, 2022, the Company extended the expiration date of the Warrants by one (1) year. G The warrant exercise price was lowered to $0.05 on December 28, 2022. H The ZNWAY warrants are associated with Automatic Monthly Investments (“AMI”) connected with participation in the unit offering announced on March 13, 2023. I On May 15, 2023, the Company announced a new Unit Offering and the related ZNWAZ warrant.
Dividend Reinvestment And Stock Purchase Plan [Member]
Stockholders' Equity (Tables) [Line Items]
Schedule of warrants transactions	The warrants balances at December 31, 2022 and transactions since January 1, 2023 are shown in the table below: Warrants Exercise Warrant Outstanding Warrants Warrants Warrants Outstanding ZNWAA $ 2.00 01/31/2024 1,498,804 - - - 1,498,804 ZNWAD $ 1.00 05/02/2023 243,853 - - (243,853 ) - ZNWAE $ 1.00 05/01/2023 2,144,099 - - (2,144,099 ) - ZNWAF $ 1.00 08/14/2023 359,435 - - - 359,435 ZNWAG $ 1.00 01/08/2024 240,068 - - - 240,068 ZNWAH $ 5.00 04/19/2023 372,400 - - (372,400 ) - ZNWAI $ 3.00 06/29/2023 640,710 - (100 ) (640,610 ) - ZNWAJ $ 1.00 10/29/2023 545,900 - - - 545,900 ZNWAK $ 0.01 02/25/2023 424,225 - (9,050 ) (415,175 ) - ZNWAL $ 2.00 08/26/2023 517,875 - - - 517,875 ZNWAM $ 0.05 09/06/2023 4,376,000 - - - 4,376,000 ZNWAN $ 1.00 05/16/2023 267,760 - (75 ) (267,685 ) - ZNWAO $ 0.25 06/12/2023 174,660 - - (174,660 ) - ZNWAQ $ 0.05 09/06/2023 23,428,348 - - - 23,428,348 ZNWAV $ 0.05 06/28/2023 - 288,500 (167,730 ) (120,770 ) - ZNWAW $ 0.05 07/13/2023 - 199,000 (124,500 ) - 74,500 ZNWAX $ 0.05 07/31/2023 - 818,500 (173,253 ) - 645,247 ZNWAY $ 0.05 09/10/2023 - 17,450 (1,650 ) - 15,800 Outstanding warrants 35,234,137 1,323,450 (476,358 ) (4,379,252 ) 31,701,977
Employees [Member]
Stockholders' Equity (Tables) [Line Items]
Schedule of weighted-average fair value of options granted using black-scholes option pricing model	The following table sets forth information about the weighted-average fair value of options granted to employees and directors during the year, using the Black Scholes option-pricing model and the weighted-average assumptions used for such grants: For the 2023 2022 Weighted-average fair value of underlying stock at grant date $ 0.06 $ 0.14 Dividend yields — — Expected volatility 136%-137 % 127%-135 % Risk-free interest rates 3.87%-3.85 % 1.37%-2.79 % Expected lives (in years) 5.00 5.00-5.50 Weighted-average grant date fair value $ 0.06 $ 0.13 For the 2023 2022 Weighted-average fair value of underlying stock at grant date — $ 0.14 Dividend yields — — Expected volatility — % 103% - 104 % Risk-free interest rates — % 1.78% - 2.83 % Expected lives (in years) — 10 Weighted-average grant date fair value — $ 0.13

Unproved Oil and Gas Properti_2

Unproved Oil and Gas Properties, Full Cost Method (Tables)	6 Months Ended
	Jun. 30, 2023
Unproved Oil and Gas Properties, Full Cost Method [Abstract]
Schedule of unproved oil and gas properties	Unproved oil and gas properties, under the full cost method, are comprised as follows: June 30, December 31, US$ US$ Excluded from amortization base: Drilling costs, and other operational related costs 2,452 2,362 Capitalized salary costs 2,394 2,342 Capitalized interest costs 1,418 1,418 Legal and seismic costs, license fees and other preparation costs 9,888 9,728 Other costs 39 39 16,191 15,889
Schedule of changes in Unproved oil and gas properties	Post Impairment of unproved oil and gas properties comprised as follows: For the three months ended For the six months ended 2023 2022 2023 2022 US$ US$ US$ US$ Excluded from amortization base: Drilling costs, and other operational related costs 44 - 55 - Capitalized salary costs - - - - Capitalized interest costs - - - - Legal costs, license fees and other preparation costs 4 - 38 - Other costs - - - - 48 - 93 -
Schedule of changes in Unproved oil and gas properties	Changes in Unproved oil and gas properties during the three and six months ended June 30, 2023 and 2022 are as follows: For the three months ended For the six months ended 2023 2022 2023 2022 US$ US$ US$ US$ Excluded from amortization base: Drilling costs, and other operational related costs 82 4,735 145 5,363 Capitalized salary costs 26 69 52 121 Capitalized interest costs - - - - Legal costs, license fees and other preparation costs 74 347 198 816 Other costs - - - - Impairment of unproved oil and gas properties (48 ) - (93 ) - *134 *5,151 *302 *6,300 * Inclusive of non-cash amounts of approximately $709,000, and $571,000 during the three months ended June 30, 2023, and 2022, respectively * Inclusive of non-cash amounts of approximately $806,000, and $1,708,000 during the six months ended June 30, 2023, and 2022, respectively

Right of Use Lease Assets and_2

Right of Use Lease Assets and Lease Obligations (Tables)	6 Months Ended
	Jun. 30, 2023
Right of Use Lease Assets and Lease Obligations [Abstract]
Schedule of operating lease assets and liabilities	The table below presents the operating lease assets and liabilities recognized on the balance sheet as of June 30, 2023 and December 31, 2022: June 30, December 31, US$ US$ Operating lease assets $ 79 $ 202 Operating lease liabilities: Current operating lease liabilities $ 67 $ 196 Non-current operating lease liabilities $ 12 $ 12 Total operating lease liabilities $ 79 $ 208
Schedule of weighted average remaining lease term and weighted average discount rate for operating leases	The Company’s weighted average remaining lease term and weighted average discount rate for operating leases as of June 30, 2023 are: June 30, Weighted average remaining lease term (years) 0.6 Weighted average discount rate 4.9 %
Schedule of future minimum lease payments	The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under non-cancellable operating leases with terms of more than one year to the total operating lease liabilities recognized on the condensed balance sheets as of June 30, 2023: US$ 2023 68 2024 11 2025 - 2026 - Thereafter - Total undiscounted future minimum lease payments 79 Less: portion representing imputed interest (1 ) Total undiscounted future minimum lease payments 78

Nature of Operations, Basis o_2

Nature of Operations, Basis of Presentation and Going Concern (Details) $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($)
Nature of Operations, Basis of Presentation and Going Concern [Abstract]
Net loss	$ 4.5
Accumulated deficit	$ 283

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Jun. 07, 2023	Mar. 12, 2020
Summary of Significant Accounting Policies (Details) [Line Items]
Common stock, par value (in Dollars per share)	$ 0.01			$ 0.01		$ 0.01	$ 0.01
Common stock equivalents (in Shares)		56,933,841	37,061,435	56,876,638	34,216,856
Oil and gas properties						$ 45,615,000
Post-impairment charges	$ 48,000			$ 93,000
Capitalized exploration costs				16,191,000		15,889,000
Allocated in additional separate assets	$ 48,000			48,000
Depreciation expense				$ 380,000		$ 371,000
Common Stock [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Common stock, par value (in Dollars per share)	$ 0.01			$ 0.01
Purchase and Sale Agreement [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Purchase price								$ 5,600,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of drilling rig & associated equipment $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Summary of Significant Accounting Policies (Details) - Schedule of drilling rig & associated equipment [Line Items]
Balance beginning	$ 6,281
Asset Additions
Asset Depreciation	(380)
Asset Disposals for Self-Consumption	(11)
Balance Ending	5,890
I-35 Drilling Rig [Member]
Summary of Significant Accounting Policies (Details) - Schedule of drilling rig & associated equipment [Line Items]
Balance beginning	5,225
Asset Additions
Asset Depreciation	(317)
Asset Disposals for Self-Consumption
Balance Ending	4,908
Rig Spare Parts [Member]
Summary of Significant Accounting Policies (Details) - Schedule of drilling rig & associated equipment [Line Items]
Balance beginning	619
Asset Additions
Asset Depreciation
Asset Disposals for Self-Consumption	(11)
Balance Ending	608
Other Drilling Assets [Member]
Summary of Significant Accounting Policies (Details) - Schedule of drilling rig & associated equipment [Line Items]
Balance beginning	437
Asset Additions
Asset Depreciation	(63)
Asset Disposals for Self-Consumption
Balance Ending	$ 374

Stockholders' Equity (Details)

Stockholders' Equity (Details)

1 Months Ended

3 Months Ended

6 Months Ended

Jul. 31, 2023 USD ($)

Jun. 09, 2021 shares

Aug. 21, 2018 $ / shares

Apr. 02, 2018 $ / shares

Dec. 06, 2017 $ / shares

Aug. 09, 2023 USD ($)

Feb. 28, 2018 USD ($) $ / shares shares

Jun. 30, 2023 USD ($) $ / shares $ / item shares

Jun. 30, 2022 USD ($) $ / shares

Jun. 30, 2023 USD ($) $ / shares $ / item shares

Jun. 30, 2022 USD ($) $ / shares shares

Dec. 31, 2025 $ / shares

Jul. 17, 2024 $ / shares

Sep. 10, 2023 $ / shares

Jul. 15, 2023 $ / shares

Jun. 28, 2023 $ / shares

Jun. 12, 2023 $ / shares

Jun. 07, 2023 $ / shares shares

May 02, 2023 $ / shares

Apr. 13, 2023 $ / shares

Dec. 31, 2022 $ / shares shares

Dec. 28, 2022 $ / shares

Mar. 21, 2022 $ / shares

May 16, 2021 $ / shares

Sep. 15, 2020

Aug. 14, 2020 $ / shares

Apr. 02, 2020

Aug. 26, 2019 $ / shares

May 29, 2019

Feb. 25, 2019 $ / shares

Dec. 10, 2018 $ / shares

Dec. 04, 2018

Oct. 29, 2018 $ / shares

May 02, 2018 $ / shares

May 22, 2017 $ / shares

May 01, 2017 $ / shares

Nov. 01, 2016 $ / shares

Jan. 13, 2015 $ / shares shares

Stockholders' Equity (Details) [Line Items]

Common stock, par value

$ 0.01

$ 0.01

$ 0.01

$ 0.01

Shares authorized to issue (in Shares) | shares

1,200,000,000

1,200,000,000

1,200,000,000

Shares purchased under option plan (in Shares) | shares

25,000

Exercise price per Share

$ 0.07

$ 0.07

$ 0.01

Fair value of stock options granted (in Dollars) | $

$ 1,500

Unrecognized compensation cost (in Dollars) | $

$ 194,000

Warrant exercise price

$ 1

1

$ 1

$ 1

$ 10

Exercise price per share

0.25

0.25

$ 0.05

$ 0.05

$ 0.05

$ 0.05

$ 0.05

$ 1

$ 2

$ 1

$ 1

Expiration term

1 year

Securities priced per unit

250

250

250

$ 250

$ 250

Common stock, par value

$ 250

250

$ 250

Warrant exercise price

$ 1

Purchase amount (in Dollars) | $

$ 250

$ 250

Consecutive trading days

15 days

Exercise price per Warrant

$ 5

Offering cost (in Dollars) | $

$ 250

CommonStockPrice

$ 250

Investments per unit

$ 50

Exercise warrant price

1

Price per share

$ 50

$ 50

Stock issuance costs (in Dollars) | $

$ 173,000

Tranches termination amount (in Dollars) | $

$ 7,500,000

$ 7,500,000

Participants investment received amount description

Plan participants, who enroll in the AMI at a minimum of $100 per month, will receive one hundred (100) ZNWAY warrants. Plan participants, who enroll in the AMI at a minimum of $250 per month, will receive two hundred and fifty (250) ZNWAY warrants. Plan participants, who enroll in the AMI at a minimum of $500 per month, will receive five hundred (500) ZNWAY warrants. The AMI program requires 90 days of participation to receive the ZNWAY warrants. Existing AMI participants are entitled to participate in this monthly program by increasing their monthly amount above the minimum $50.00 per month.

Automatic monthly investments (in Dollars per Item) | $ / item

50

50

Raised amount (in Dollars) | $

$ 2,553,000

$ 12,993,000

$ 1,761,000

$ 1,566,000

Common Stock [Member]

Stockholders' Equity (Details) [Line Items]

Common stock, par value

$ 0.01

$ 0.01

Exercise price per Share

$ 1

Share issued (in Shares) | shares

1

Exercise price per share

0.25

0.25

ZNWAE warrants [Member]

Stockholders' Equity (Details) [Line Items]

Expiration term

1 year

ZNWAZ Warrants [Member]

Stockholders' Equity (Details) [Line Items]

Warrant exercise price

[1]

0.25

0.25

Exercise price per share

$ 0.25

Warrant [Member]

Stockholders' Equity (Details) [Line Items]

Exercise price per Share

0.01

$ 4

Share issued (in Shares) | shares

3

Warrant exercise price

5

$ 5

$ 0.25

Expiration term

2 years

1 year

1 year

1 year

Stock or Unit Option Plan Expense (in Dollars) | $

$ 250

Warrant [Member]

Stockholders' Equity (Details) [Line Items]

Warrant exercise price

$ 0.05

Expiration term

1 year

2 years

1 year

1 year

Subsequent Event [Member]

Stockholders' Equity (Details) [Line Items]

Raised amount (in Dollars) | $

Subsequent Event [Member] | Warrant [Member]

Stockholders' Equity (Details) [Line Items]

Warrant exercise price

$ 0.05

Five Senior Officers [Member]

Stockholders' Equity (Details) [Line Items]

Shares purchased under option plan (in Shares) | shares

175,000

Exercise price per Share

0.0615

$ 0.0615

Fair value of stock options granted (in Dollars) | $

$ 9,000

Exercise price per share

$ 0.01

One Senior Officer [Member]

Stockholders' Equity (Details) [Line Items]

Shares purchased under option plan (in Shares) | shares

25,000

25,000

Exercise price per Share

0.01

$ 0.01

$ 0.01

$ 0.01

Fair value of stock options granted (in Dollars) | $

$ 1,500

$ 4,000

Six Senior Officers [Member]

Stockholders' Equity (Details) [Line Items]

Shares purchased under option plan (in Shares) | shares

175,000

One Senior Officer and One Staff [Member]

Stockholders' Equity (Details) [Line Items]

Shares purchased under option plan (in Shares) | shares

300,000

Exercise price per Share

0.01

$ 0.01

Fair value of stock options granted (in Dollars) | $

$ 39,000

One Board [Member]

Stockholders' Equity (Details) [Line Items]

Shares purchased under option plan (in Shares) | shares

25,000

Exercise price per Share

0.11

$ 0.11

Fair value of stock options granted (in Dollars) | $

$ 2,000

Five Senior Officers and Four Staff [Member]

Stockholders' Equity (Details) [Line Items]

Shares purchased under option plan (in Shares) | shares

1,600,000

Exercise price per Share

0.1529

$ 0.1529

Fair value of stock options granted (in Dollars) | $

209,000

$ 209,000

Seven Board [Member]

Stockholders' Equity (Details) [Line Items]

Shares purchased under option plan (in Shares) | shares

1,400,000

Exercise price per Share

0.1529

$ 0.1529

Fair value of stock options granted (in Dollars) | $

$ 182,000

$ 182,000

Four Staff [Member]

Stockholders' Equity (Details) [Line Items]

Shares purchased under option plan (in Shares) | shares

160,000

Exercise price per Share

0.01

$ 0.01

Stock option plan, exercisable date

January 17, 2032

Fair value of stock options granted (in Dollars) | $

$ 23,000

Six Staff [Member]

Stockholders' Equity (Details) [Line Items]

Shares purchased under option plan (in Shares) | shares

200,000

Exercise price per Share

0.14

$ 0.14

Eight Board [Member]

Stockholders' Equity (Details) [Line Items]

Shares purchased under option plan (in Shares) | shares

3,200,000

Exercise price per Share

0.15

$ 0.15

Fair value of stock options granted (in Dollars) | $

$ 393,000

New Unit Program [Member] | Znwaf [Member]

Stockholders' Equity (Details) [Line Items]

Exercise price per Share

$ 1

Forecast [Member]

Stockholders' Equity (Details) [Line Items]

Warrant exercise price

$ 0.25

Forecast [Member] | Warrant [Member]

Stockholders' Equity (Details) [Line Items]

Warrant exercise price

$ 0.25

2021 Omnibus Incentive Stock Option Plan [Member]

Stockholders' Equity (Details) [Line Items]

Shares of common stock (in Shares) | shares

38,000,000

Exercisable period

10 years

2021 Omnibus Incentive Stock Option Plan [Member] | Five Senior Officers [Member]

Stockholders' Equity (Details) [Line Items]

Shares purchased under option plan (in Shares) | shares

3,210,000

Exercise price per Share

0.15

$ 0.15

Fair value of stock options granted (in Dollars) | $

$ 394,000

$ 394,000

2021 Omnibus Incentive Stock Option Plan [Member] | One Staff [Member]

Stockholders' Equity (Details) [Line Items]

Stock option plan, exercisable date

vested upon grant and are exercisable through January 4, 2033.

2021 Omnibus Incentive Stock Option Plan [Member] | One Senior Officer [Member]

Stockholders' Equity (Details) [Line Items]

Shares purchased under option plan (in Shares) | shares

1,090,000

Exercise price per Share

0.01

$ 0.01

Fair value of stock options granted (in Dollars) | $

$ 149,000

2021 Omnibus Incentive Stock Option Plan [Member] | Six Senior Officers [Member]

Stockholders' Equity (Details) [Line Items]

Exercise price per Share

0.1529

$ 0.1529

Fair value of stock options granted (in Dollars) | $

$ 22,000

2021 Omnibus Incentive Stock Option Plan [Member] | One Board [Member]

Stockholders' Equity (Details) [Line Items]

Shares purchased under option plan (in Shares) | shares

200,000

Exercise price per Share

0.01

$ 0.01

Fair value of stock options granted (in Dollars) | $

$ 29,000

2021 Omnibus Incentive Stock Option Plan [Member] | Six Staff [Member]

Stockholders' Equity (Details) [Line Items]

Fair value of stock options granted (in Dollars) | $

$ 26,000

$ 26,000

2021 Omnibus Incentive Stock Option Plan [Member] | Two Consultants [Member]

Stockholders' Equity (Details) [Line Items]

Shares purchased under option plan (in Shares) | shares

40,000

Exercise price per Share

$ 0.14

$ 0.14

Fair value of stock options granted (in Dollars) | $

$ 5,000

$ 5,000

2011 Equity Incentive Stock Option Plan [Member] | Six Senior Officers [Member]

Stockholders' Equity (Details) [Line Items]

Stock option plan, exercisable date

January 4, 2032

Minimum [Member]

Stockholders' Equity (Details) [Line Items]

Stock issuance costs (in Dollars) | $

$ 173,000

Maximum [Member]

Stockholders' Equity (Details) [Line Items]

Stock issuance costs (in Dollars) | $

$ 2,553,000

Znwaf [Member]

Stockholders' Equity (Details) [Line Items]

Common stock, par value

$ 5

$ 5

Common Stock [Member]

Stockholders' Equity (Details) [Line Items]

Shares of common stock (in Shares) | shares

50

Purchase amount (in Dollars) | $

$ 250

$ 250

Exercise price per Warrant

$ 5

Purchase of additional shares (in Shares) | shares

50

Stock or Unit Option Plan Expense (in Dollars) | $

$ 250

Common Stock [Member] | Warrant [Member]

Stockholders' Equity (Details) [Line Items]

Warrant exercise price

$ 0.25

$ 0.25

Additional shares (in Shares) | shares

200

ZNWAG [Member]

Stockholders' Equity (Details) [Line Items]

Exercise price per Warrant

$ 1

ZNHAH [Member]

Stockholders' Equity (Details) [Line Items]

Exercise price per Warrant

$ 5

ZNWAH [Member]

Stockholders' Equity (Details) [Line Items]

Expiration term

2 years

1 year

ZNWAL [Member]

Stockholders' Equity (Details) [Line Items]

Warrant exercise price

2

$ 2

Offering cost, description

The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) two hundred and fifty (250) shares of Common Stock and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $2.00. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the Unit Program with the purchase of at least one Unit and also enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional twenty-five (25) warrants at an exercise price of $2.00 during this Unit Option Program. The twenty-five (25) additional warrants were for enrolling into the AMI program.

ZNWAO [Member

Stockholders' Equity (Details) [Line Items]

Warrant exercise price

0.25

$ 0.25

ZNWAS [Member]

Stockholders' Equity (Details) [Line Items]

Expiration date, description

Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on June 18, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAQ.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants were issued on May 5, 2022 and were exercisable through July 6, 2023 at a revised per share exercise price of $.05. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.On June 16, 2023, the Company extended the termination date of the ZNWAQ warrant from July 6, 2023 to September 6, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension.Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet to a participant. After conclusion of the program on September 15, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired.Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on November 15, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and warrants that will be acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant shall have the company notation of “ZNWAS.” The warrants will not be registered for trading on the OTCQX or any other stock market or trading market. The warrants will be issued and become exercisable on November 15, 2025 and continue to be exercisable through December 31, 2025 at a revised per share exercise price of $.25.

ZNWAU Warrants [Member]

Stockholders' Equity (Details) [Line Items]

Warrant exercise price

0.25

$ 0.25

Amended and Restated Certificate of Incorporation [Member] | Minimum [Member]

Stockholders' Equity (Details) [Line Items]

Shares authorized to issue (in Shares) | shares

800,000,000

Amended and Restated Certificate of Incorporation [Member] | Maximum [Member]

Stockholders' Equity (Details) [Line Items]

Shares authorized to issue (in Shares) | shares

1,200,000,000

ZNWAM Warrant [Member]

Stockholders' Equity (Details) [Line Items]

Expiration term

1 year

ZNWAL [Member]

Stockholders' Equity (Details) [Line Items]

Warrant exercise price

1

1

Exercise price per share

1

1

Securities priced per unit

250

250

Investments per unit

$ 50

ZNWAL [Member] | Common Stock [Member]

Stockholders' Equity (Details) [Line Items]

Offering cost, description

The unit offering consisted of Units of the Company’s securities where each Unit (priced at $250.00 each) was comprised of (i) the number of Common Stock shares represented by the high-low average on the purchase date and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $.25. The investor’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants acquired under the Units purchased. For Plan participants who enrolled into the unit offering with the purchase of at least one Unit or who enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month or more, received an additional fifty (50) warrants at an exercise price of $.25 during this Unit Option Program. The fifty (50) additional warrants were for enrolling into the AMI program.

Znwao Warrant [Member]

Stockholders' Equity (Details) [Line Items]

Exercise price per share

0.25

$ 0.25

Securities priced per unit

250

250

OTCQX warrants [Member]

Stockholders' Equity (Details) [Line Items]

Exercise price per share

0.05

$ 0.05

Additional shares (in Shares) | shares

(500)

OTCQX warrants [Member] | Common Stock [Member]

Stockholders' Equity (Details) [Line Items]

Warrant exercise price

0.25

$ 0.25

ZNWAV Warrants [Member]

Stockholders' Equity (Details) [Line Items]

Warrant exercise price

0.05

0.05

ZNWAY [Member]

Stockholders' Equity (Details) [Line Items]

Warrant exercise price

$ 0.05

$ 0.05

[1]On May 15, 2023, the Company announced a new Unit Offering and the related ZNWAZ warrant.

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Schedule of stock option transactions - Employee Stock Option [Member] - $ / shares	6 Months Ended
	Jun. 30, 2023
Stockholders' Equity (Details) - Schedule of stock option transactions [Line Items]
Number of shares, Outstanding, Beginning	26,391,250
Weighted Average exercise price, Outstanding, Beginning	$ 0.3
Number of shares, Granted to employees, officers, directors and others	225,000
Weighted Average exercise price, Granted to employees, officers, directors and others	$ 0.06
Number of shares, Expired/Cancelled/Forfeited	(25,000)
Weighted Average exercise price, Expired/Cancelled/Forfeited	$ 1.33
Number of shares, Exercised	(150,000)
Weighted Average exercise price, Exercised	$ 0.07
Number of shares, Outstanding, Ending	26,441,250
Weighted Average exercise price, Outstanding, Ending	$ 0.3
Number of shares, Exercisable	21,286,250
Weighted Average exercise price, Exercisable	$ 0.32

Stockholders' Equity (Details_2

Stockholders' Equity (Details) - Schedule of stock options outstanding	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.18
Number Outstanding (in Shares) | shares	5,155,000
Weighted Average Exercise price	$ 0.18
Non-vested [Member] | Ranges One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.18
Number Outstanding (in Shares) | shares	5,155,000
Weighted average remaining contractual life (years)	9 years 2 months 26 days
Weighted Average Exercise price	$ 0.18
Non-vested [Member] | Ranges Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Ten [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Eleven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twelve [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fourteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fifteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Sixteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Seventeen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Eighteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Nineteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Twenty Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Thirty Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fourty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Range Fourty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fourty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Range Fourty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Range Fourty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Range Fourty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Range Fourty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Range Fourty Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fourty Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fourty Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fifty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fifty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fifty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Non-vested [Member] | Ranges Fifty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares	21,286,250
Weighted Average Exercise price	$ 0.32
Vested [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	0.01
Vested [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	4.15
Vested [Member] | Ranges One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	10,000
Weighted average remaining contractual life (years)	4 months 13 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	5,000
Weighted average remaining contractual life (years)	11 months 12 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	20,000
Weighted average remaining contractual life (years)	2 years 11 months 4 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	130,000
Weighted average remaining contractual life (years)	3 years 6 months 3 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	50,000
Weighted average remaining contractual life (years)	3 years 6 months 7 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	60,000
Weighted average remaining contractual life (years)	3 years 9 months 18 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	200,000
Weighted average remaining contractual life (years)	3 years 10 months 20 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	40,000
Weighted average remaining contractual life (years)	4 years 3 months 3 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	70,000
Weighted average remaining contractual life (years)	4 years 6 months 3 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Ten [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	4 years 6 months 7 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Eleven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	30,000
Weighted average remaining contractual life (years)	4 years 8 months 1 day
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twelve [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	4,000
Weighted average remaining contractual life (years)	4 years 9 months 7 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Thirteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	5 years 6 months 10 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Fourteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	35,000
Weighted average remaining contractual life (years)	6 years 2 months 19 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Fifteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	150,000
Weighted average remaining contractual life (years)	6 years 4 months 20 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Sixteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	35,000
Weighted average remaining contractual life (years)	6 years 6 months 7 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Seventeen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	75,000
Weighted average remaining contractual life (years)	7 years 6 months 7 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Eighteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	200,000
Weighted average remaining contractual life (years)	7 years 10 months 24 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Nineteen [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	300,000
Weighted average remaining contractual life (years)	8 years 18 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	10,000
Weighted average remaining contractual life (years)	8 years 2 months 4 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	500,000
Weighted average remaining contractual life (years)	8 years 6 months 7 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	55,000
Weighted average remaining contractual life (years)	8 years 6 months 21 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	960,000
Weighted average remaining contractual life (years)	8 years 9 months 18 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	75,000
Weighted average remaining contractual life (years)	9 years 1 month 17 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	10,000
Weighted average remaining contractual life (years)	9 years 2 months 4 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	795,000
Weighted average remaining contractual life (years)	9 years 2 months 26 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	9 years 6 months 7 days
Weighted Average Exercise price	$ 0.01
Vested [Member] | Ranges Twenty Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.06
Number Outstanding (in Shares) | shares	50,000
Weighted average remaining contractual life (years)	9 years 6 months 7 days
Weighted Average Exercise price	$ 0.06
Vested [Member] | Ranges Twenty Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.07
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	9 years 11 months 12 days
Weighted Average Exercise price	$ 0.07
Vested [Member] | Ranges Thirty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.14
Number Outstanding (in Shares) | shares	240,000
Weighted average remaining contractual life (years)	8 years 6 months 21 days
Weighted Average Exercise price	$ 0.14
Vested [Member] | Ranges Thirty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.15
Number Outstanding (in Shares) | shares	3,200,000
Weighted average remaining contractual life (years)	8 years 6 months 7 days
Weighted Average Exercise price	$ 0.15
Vested [Member] | Ranges Thirty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.15
Number Outstanding (in Shares) | shares	6,410,000
Weighted average remaining contractual life (years)	8 years 9 months 18 days
Weighted Average Exercise price	$ 0.15
Vested [Member] | Ranges Thirty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.16
Number Outstanding (in Shares) | shares	340,000
Weighted average remaining contractual life (years)	2 years 5 months 12 days
Weighted Average Exercise price	$ 0.16
Vested [Member] | Ranges Thirty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.16
Number Outstanding (in Shares) | shares	75,000
Weighted average remaining contractual life (years)	6 years 5 months 12 days
Weighted Average Exercise price	$ 0.16
Vested [Member] | Ranges Thirty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.18
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	2 years 5 months 4 days
Weighted Average Exercise price	$ 0.18
Vested [Member] | Ranges Thirty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.24
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	9 years 1 month 6 days
Weighted Average Exercise price	$ 0.24
Vested [Member] | Ranges Thirty Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.24
Number Outstanding (in Shares) | shares	118,000
Weighted average remaining contractual life (years)	9 years 1 month 17 days
Weighted Average Exercise price	$ 0.24
Vested [Member] | Ranges Thirty Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.25
Number Outstanding (in Shares) | shares	50,000
Weighted average remaining contractual life (years)	8 years 2 months 4 days
Weighted Average Exercise price	$ 0.25
Vested [Member] | Ranges Thirty Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.25
Number Outstanding (in Shares) | shares	363,000
Weighted average remaining contractual life (years)	8 years 2 months 4 days
Weighted Average Exercise price	$ 0.25
Vested [Member] | Ranges Fourty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.28
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	2 years 2 months 4 days
Weighted Average Exercise price	$ 0.28
Vested [Member] | Range Fourty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.28
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	6 years 2 months 4 days
Weighted Average Exercise price	$ 0.28
Vested [Member] | Ranges Fourty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.29
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	3 years 11 months 15 days
Weighted Average Exercise price	$ 0.29
Vested [Member] | Range Fourty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.39
Number Outstanding (in Shares) | shares	1,435,000
Weighted average remaining contractual life (years)	8 years 10 days
Weighted Average Exercise price	$ 0.39
Vested [Member] | Range Fourty Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.59
Number Outstanding (in Shares) | shares	1,400,000
Weighted average remaining contractual life (years)	3 years 10 months 20 days
Weighted Average Exercise price	$ 0.59
Vested [Member] | Range Fourty Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.59
Number Outstanding (in Shares) | shares	1,600,000
Weighted average remaining contractual life (years)	7 years 10 months 24 days
Weighted Average Exercise price	$ 0.59
Vested [Member] | Range Fourty Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.92
Number Outstanding (in Shares) | shares	350,000
Weighted average remaining contractual life (years)	3 years 6 months 7 days
Weighted Average Exercise price	$ 0.92
Vested [Member] | Range Fourty Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.92
Number Outstanding (in Shares) | shares	550,000
Weighted average remaining contractual life (years)	7 years 6 months 7 days
Weighted Average Exercise price	$ 0.92
Vested [Member] | Ranges Fourty Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.38
Number Outstanding (in Shares) | shares	105,307
Weighted average remaining contractual life (years)	1 year 6 months 3 days
Weighted Average Exercise price	$ 1.38
Vested [Member] | Ranges Fourty Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.67
Number Outstanding (in Shares) | shares	405,943
Weighted average remaining contractual life (years)	1 year 3 months 3 days
Weighted Average Exercise price	$ 1.67
Vested [Member] | Ranges Fifty [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.75
Number Outstanding (in Shares) | shares	250,000
Weighted average remaining contractual life (years)	7 days
Weighted Average Exercise price	$ 1.75
Vested [Member] | Ranges Fifty One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.78
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	1 year 2 months 4 days
Weighted Average Exercise price	$ 1.78
Vested [Member] | Ranges Fifty Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 2.31
Number Outstanding (in Shares) | shares	250,000
Weighted average remaining contractual life (years)	6 months 3 days
Weighted Average Exercise price	$ 2.31
Vested [Member] | Ranges Fifty Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 4.15
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	1 year 3 days
Weighted Average Exercise price	$ 4.15

Stockholders' Equity (Details_3

Stockholders' Equity (Details) - Schedule of weighted-average fair value of options granted using black-scholes option pricing model - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Employee [Member]
Stockholders' Equity (Details) - Schedule of weighted-average fair value of options granted using black-scholes option pricing model [Line Items]
Weighted-average fair value of underlying stock at grant date (in Dollars per share)	$ 0.06	$ 0.14
Dividend yields
Expected lives (in years)	5 years
Weighted-average grant date fair value (in Dollars per share)	$ 0.06	$ 0.13
Non-Employees [Member]
Stockholders' Equity (Details) - Schedule of weighted-average fair value of options granted using black-scholes option pricing model [Line Items]
Weighted-average fair value of underlying stock at grant date (in Dollars per share)		$ 0.14
Dividend yields
Expected lives (in years)		10 years
Weighted-average grant date fair value (in Dollars per share)		$ 0.13
Minimum [Member] | Employee [Member]
Stockholders' Equity (Details) - Schedule of weighted-average fair value of options granted using black-scholes option pricing model [Line Items]
Expected volatility	136%	127%
Risk-free interest rates	3.87%	1.37%
Expected lives (in years)		5 years
Minimum [Member] | Non-Employees [Member]
Stockholders' Equity (Details) - Schedule of weighted-average fair value of options granted using black-scholes option pricing model [Line Items]
Expected volatility		103%
Risk-free interest rates		1.78%
Maximum [Member] | Employee [Member]
Stockholders' Equity (Details) - Schedule of weighted-average fair value of options granted using black-scholes option pricing model [Line Items]
Expected volatility	137%	135%
Risk-free interest rates	3.85%	2.79%
Expected lives (in years)		5 years 6 months
Maximum [Member] | Non-Employees [Member]
Stockholders' Equity (Details) - Schedule of weighted-average fair value of options granted using black-scholes option pricing model [Line Items]
Expected volatility		104%
Risk-free interest rates		2.83%

Stockholders' Equity (Details_4

Stockholders' Equity (Details) - Schedule of the compensation cost of warrant and option issuances - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Stockholders' Equity (Details) - Schedule of the compensation cost of warrant and option issuances [Line Items]
Compensation cost of warrant and option issuances		$ 10		$ 17
Employees And Directors [Member]
Stockholders' Equity (Details) - Schedule of the compensation cost of warrant and option issuances [Line Items]
Compensation cost of warrant and option issuances	242	417
Non-employees [Member]
Stockholders' Equity (Details) - Schedule of the compensation cost of warrant and option issuances [Line Items]
Compensation cost of warrant and option issuances			656	631
Unproved Oil & Gas properties [Member]
Stockholders' Equity (Details) - Schedule of the compensation cost of warrant and option issuances [Line Items]
Compensation cost of warrant and option issuances		$ 3	$ 2	$ 4

Stockholders' Equity (Details_5

Stockholders' Equity (Details) - Schedule of warrants transactions - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Class of Warrant or Right [Line Items]
Outstanding warrants, Beginning Balance		35,234,137
Warrants Issued	1,323,450
Warrants Exercised	(476,358)
Warrants Expired	(4,379,252)
Outstanding warrants, Ending Balance	31,701,977
ZNWAA Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$ 2
Warrant Termination Date		Jan. 31, 2024
Outstanding warrants, Beginning Balance		1,498,804
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding warrants, Ending Balance	1,498,804
ZNWAD Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$ 1
Warrant Termination Date		May 02, 2023
Outstanding warrants, Beginning Balance		243,853
Warrants Issued
Warrants Exercised
Warrants Expired	(243,853)
Outstanding warrants, Ending Balance
ZNWAE Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$ 1
Warrant Termination Date		May 01, 2023
Outstanding warrants, Beginning Balance		2,144,099
Warrants Issued
Warrants Exercised
Warrants Expired	(2,144,099)
Outstanding warrants, Ending Balance
ZNWAF [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$ 1
Warrant Termination Date		Aug. 14, 2023
Outstanding warrants, Beginning Balance		359,435
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding warrants, Ending Balance	359,435
ZNWAG [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$ 1
Warrant Termination Date		Jan. 08, 2024
Outstanding warrants, Beginning Balance		240,068
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding warrants, Ending Balance	240,068
ZNWAH [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$ 5
Warrant Termination Date		Apr. 19, 2023
Outstanding warrants, Beginning Balance		372,400
Warrants Issued
Warrants Exercised
Warrants Expired	(372,400)
Outstanding warrants, Ending Balance
ZNWAI Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$ 3
Warrant Termination Date		Jun. 29, 2023
Outstanding warrants, Beginning Balance		640,710
Warrants Issued
Warrants Exercised	(100)
Warrants Expired	(640,610)
Outstanding warrants, Ending Balance
ZNWAJ Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$ 1
Warrant Termination Date		Oct. 29, 2023
Outstanding warrants, Beginning Balance		545,900
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding warrants, Ending Balance	545,900
ZNWAK Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$ 0.01
Warrant Termination Date		Feb. 25, 2023
Outstanding warrants, Beginning Balance		424,225
Warrants Issued
Warrants Exercised	(9,050)
Warrants Expired	(415,175)
Outstanding warrants, Ending Balance
ZNWAL Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$ 2
Warrant Termination Date		Aug. 26, 2023
Outstanding warrants, Beginning Balance		517,875
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding warrants, Ending Balance	517,875
ZNWAM Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$ 0.05
Warrant Termination Date		Sep. 06, 2023
Outstanding warrants, Beginning Balance		4,376,000
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding warrants, Ending Balance	4,376,000
ZNWAN Warrants [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$ 1
Warrant Termination Date		May 16, 2023
Outstanding warrants, Beginning Balance		267,760
Warrants Issued
Warrants Exercised	(75)
Warrants Expired	(267,685)
Outstanding warrants, Ending Balance
ZNWAO Warrant [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$ 0.25
Warrant Termination Date		Jun. 12, 2023
Outstanding warrants, Beginning Balance		174,660
Warrants Issued
Warrants Exercised
Warrants Expired	(174,660)
Outstanding warrants, Ending Balance
ZNWAQ Warrant [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$ 0.05
Warrant Termination Date		Sep. 06, 2023
Outstanding warrants, Beginning Balance		23,428,348
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding warrants, Ending Balance	23,428,348
ZNWAV Warrant [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$ 0.05
Warrant Termination Date		Jun. 28, 2023
Outstanding warrants, Beginning Balance
Warrants Issued	288,500
Warrants Exercised	(167,730)
Warrants Expired	(120,770)
Outstanding warrants, Ending Balance
ZNWAW Warrant [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$ 0.05
Warrant Termination Date		Jul. 13, 2023
Outstanding warrants, Beginning Balance
Warrants Issued	199,000
Warrants Exercised	(124,500)
Warrants Expired
Outstanding warrants, Ending Balance	74,500
ZNWAX Warrant [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$ 0.05
Warrant Termination Date		Jul. 31, 2023
Outstanding warrants, Beginning Balance
Warrants Issued	818,500
Warrants Exercised	(173,253)
Warrants Expired
Outstanding warrants, Ending Balance	645,247
ZNWAY Warrant [Member] | Warrant Transactions [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$ 0.05
Warrant Termination Date		Sep. 10, 2023
Outstanding warrants, Beginning Balance
Warrants Issued	17,450
Warrants Exercised	(1,650)
Warrants Expired
Outstanding warrants, Ending Balance	15,800

Stockholders' Equity (Details_6

Stockholders' Equity (Details) - Schedule of warrants description	6 Months Ended
	Jun. 30, 2023 $ / shares
ZNWAZ Warrants [Member]
Schedule of Warrants Description [Abstract]
Period of Grant	May – June 2023	[1]
Exercise Price	$ 0.25	[1]
Expiration Date	July 17, 2024	[1]
Investor [Member] | ZNWAA Warrants [Member]
Schedule of Warrants Description [Abstract]
Period of Grant	March 2013 – December 2014	[2],[3],[4]
Exercise Price	$ 2	[2],[3],[4]
Expiration Date	January 31, 2024	[2],[3],[4]
Investor [Member] | ZNWAF Warrants [Member]
Schedule of Warrants Description [Abstract]
Period of Grant	May 2017 – July 2017	[3],[4],[5]
Exercise Price	$ 1	[3],[4],[5]
Expiration Date	August 14, 2023	[3],[4],[5]
Investor [Member] | ZNWAG Warrants [Member]
Schedule of Warrants Description [Abstract]
Period of Grant	October 2017 – December 2017	[2],[4]
Exercise Price	$ 1	[2],[4]
Expiration Date	January 08, 2024	[2],[4]
Investor [Member] | ZNWAJ Warrants [Member]
Schedule of Warrants Description [Abstract]
Period of Grant	August 2018 – September 2018	[3],[4]
Exercise Price	$ 1	[3],[4]
Expiration Date	October 29, 2023	[3],[4]
Investor [Member] | ZNWAL Warrants [Member]
Schedule of Warrants Description [Abstract]
Period of Grant	July 2019 – August 2019	[4]
Exercise Price	$ 2	[4]
Expiration Date	August 26, 2023	[4]
Investor [Member] | ZNWAM Warrants [Member]
Schedule of Warrants Description [Abstract]
Period of Grant	January 2021 – March 2021	[6],[7]
Exercise Price	$ 0.05	[6],[7]
Expiration Date	September 6, 2023	[6],[7]
Investor [Member] | ZNWAX Warrants [Member]
Schedule of Warrants Description [Abstract]
Period of Grant	June 2021	[6],[7]
Exercise Price	$ 0.05	[6],[7]
Expiration Date	September 6, 2023	[6],[7]
Investor [Member] | ZNWAS Warrants [Member]
Schedule of Warrants Description [Abstract]
Period of Grant	August 2021 – March 2022	[8]
Exercise Price	$ 0.25	[8]
Expiration Date	December 31, 2025	[8]
Investor [Member] | ZNWAT Warrants [Member]
Schedule of Warrants Description [Abstract]
Period of Grant	August – September 2022	[8]
Exercise Price	$ 0.25	[8]
Expiration Date	December 31, 2025	[8]
Investor [Member] | ZNWAU Warrants [Member]
Schedule of Warrants Description [Abstract]
Period of Grant	October – November 2022	[8]
Exercise Price	$ 0.25	[8]
Expiration Date	December 31, 2025	[8]
Investor [Member] | ZNWAY Warrants [Member]
Schedule of Warrants Description [Abstract]
Period of Grant	March – April 2023	[9]
Exercise Price	$ 0.05	[9]
Expiration Date	Sept 10, 2023	[9]
[1]On May 15, 2023, the Company announced a new Unit Offering and the related ZNWAZ warrant.[2] On December 14, 2022, the Company extended the expiration date of the Warrants by one (1) year. On May 29, 2019, the Company extended the expiration date of the Warrants by one (1) year. On September 15, 2020, the Company extended the expiration date of the Warrants by two (2) years. On December 4, 2018, the Company extended the expiration date of the Warrants by one (1) year. On March 21, 2022, the Company extended the expiration date of the Warrants by one (1) year. On June 16, 2023, the Company extended the expiration date of the Warrants to September 6, 2023. The warrant exercise price was lowered to $0.05 on December 28, 2022. These warrants will be issued and become exercisable beginning on November 15, 2025 and expire on December 31, 2025.

Unproved Oil and Gas Properti_3

Unproved Oil and Gas Properties, Full Cost Method (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Unproved Oil and Gas Properties, Full Cost Method [Abstract]
Inclusive of non-cash amounts	$ 709,000	$ 571,000	$ 806,000	$ 1,708,000

Unproved Oil and Gas Properti_4

Unproved Oil and Gas Properties, Full Cost Method (Details) - Schedule of unproved oil and gas properties - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Schedule of unproved oil and gas properties [Abstract]
Drilling costs, and other operational related costs	$ 2,452	$ 2,362
Capitalized salary costs	2,394	2,342
Capitalized interest costs	1,418	1,418
Legal and seismic costs, license fees and other preparation costs	9,888	9,728
Other costs	39	39
Total unproved oil and gas properties	$ 16,191	$ 15,889

Unproved Oil and Gas Properti_5

Unproved Oil and Gas Properties, Full Cost Method (Details) - Schedule of impairment of unproved oil and gas properties - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Schedule Of Impairment Of Unproved Oil And Gas Properties Abstract
Drilling costs, and other operational related costs	$ 44		$ 55
Capitalized salary costs
Capitalized interest costs
Legal costs, license fees and other preparation costs	4		38
Other costs
Total unproved oil and gas properties	$ 48		$ 93

Unproved Oil and Gas Properti_6

Unproved Oil and Gas Properties, Full Cost Method (Details) - Schedule of changes in Unproved oil and gas properties - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2023		Jun. 30, 2022		Jun. 30, 2023		Jun. 30, 2022
Schedule Of Changes In Unproved Oil And Gas Properties Abstract
Drilling costs, and other operational related costs	$ 82		$ 4,735		$ 145		$ 5,363
Capitalized salary costs	26		69		52		121
Capitalized interest costs
Legal costs, license fees and other preparation costs	74		347		198		816
Other costs
Impairment of unproved oil and gas properties	(48)				(93)
Total unproved oil and gas properties		[1]		[2]		[1]		[2]
[1] Inclusive of non-cash amounts of approximately $709,000, and $571,000 during the three months ended June 30, 2023, and 2022, respectively Inclusive of non-cash amounts of approximately $806,000, and $1,708,000 during the six months ended June 30, 2023, and 2022, respectively

Right of Use Lease Assets and_3

Right of Use Lease Assets and Lease Obligations (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Right of Use Leases Assets and Leases Obligations [Abstract]
Operating lease costs	$ 57,000	$ 68,000	$ 126,000	$ 137,000
Operating lease liabilities	57,000	71,000	127,000	143,000
Right-of-use assets obtained in exchange for new operating lease liabilities		$ 136,000		$ 136,000

Right of Use Lease Assets and_4

Right of Use Lease Assets and Lease Obligations (Details) - Schedule of operating lease assets and liabilities - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Schedule Of Operating Lease Assets And Liabilities Abstract
Operating lease assets	$ 79	$ 202
Operating lease liabilities:
Current operating lease liabilities	67	196
Non-current operating lease liabilities	12	12
Total operating lease liabilities	$ 79	$ 208

Right of Use Lease Assets and_5

Right of Use Lease Assets and Lease Obligations (Details) - Schedule of weighted average remaining lease term and weighted average discount rate for operating leases	Jun. 30, 2023
Schedule Of Weighted Average Remaining Lease Term And Weighted Average Discount Rate For Operating Leases [Abstract]
Weighted average remaining lease term (years)	7 months 6 days
Weighted average discount rate	4.90%

Right of Use Lease Assets and_6

Right of Use Lease Assets and Lease Obligations (Details) - Schedule of future minimum lease payments $ in Thousands	Jun. 30, 2023 USD ($)
Schedule Of Future Minimum Lease Payments Under Non Cancellable Operating Leases [Abstract]
2023	$ 68
2024	11
2025
2026
Thereafter
Total undiscounted future minimum lease payments	79
Less: portion representing imputed interest	(1)
Total undiscounted future minimum lease payments	$ 78

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Commitments and Contingencies (Details) [Line Items]
Accrued license costs
Bank guarantees to government	$ 930,000	930,000
Aggregate guarantee amount	1,018,000	$ 1,018,000
Risk percentage		5.10%	13.20%
Short-term bank deposits	$ 1,558,000	$ 1,558,000
Weighted average annual interest rate	4.18%	3.21%
Product Concentration Risk [Member]
Commitments and Contingencies (Details) [Line Items]
Bank guarantees to others	$ 88,000	$ 88,000